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“ La struttura alare del calabrone, in relazione al suo peso, 
 non è adatta al volo, ma lui non lo sa e vola lo stesso” 
 
A. Einstein 
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1. Summary 
 
Amylin, also known as islet amyloid polypeptide, is co-secreted with insulin by 
pancreatic β-cells in response to nutrient stimuli. Amylin reduces food intake and 
body weight and also acts as adiposity signal to control energy expenditure (EE).  
Circulating amylin acts centrally by primarily activating neurons of the area postrema 
(AP), a circumventricular organ (CVO) located in the hindbrain. Amylin receptors 
(AMYs) are dimers of the calcitonin-like receptor isoform a (CTRa) and of one 
member of the receptor activity modifying proteins (RAMPs). The presence of CTRa 
and the RAMPs has been described in several brain areas, including the AP.  
Amylin synergistically interacts with the adipokine leptin to reduce food intake and 
body weight. Although, brain areas where this interaction occurs have not been 
identified yet, the AP recently emerged as a good candidate. However, evidence of 
co-expression of all the subunits of the AMYs and leptin receptors (LepRb) in 
individual AP-neurons is still lacking. Therefore we applied a combination of laser 
capture microdissection and single-cell qPCR to investigate the co-expression of 
AMYs components and LepRb in individual AP-neurons. Our results demonstrated 
that CTRa and one or more RAMPs transcripts are co-expressed in single AP-
neurons. Moreover, acute amylin treatment differentially regulates its own receptor: 
while CTRa is un-affected, RAMP1 and RAMP3 mRNAs are consistently down-
regulated. On the contrary, RAMP2 mRNA is up-regulated. Furthermore, 30% of 
amylin-activated AP-neurons, which co-express all the transcripts necessary to 
generate a functional AMY, also co-express LepRb mRNA.  
 
Interestingly, these results outline the possibility that more than one RAMP can be co-
expressed with CTRa, raising the question whether different CTRa/RAMPs might 
mediate different physiological effects in the feeding behavior. Indeed, not only does 
RAMP1 generate an AMY1 by coupling with CTR, but it also has the potential to 
bind to the calcitonin-like receptor and generate a calcitonin-gene-related peptide 
receptor (CGRP). Since both amylin and CGRP decrease food intake and body weight 
we speculate that RAMP1 might exert a critical role in the regulation of energy 
balance. In fact, transgenic mice expressing the human (h) RAMP1 (Nestin/hRAMP1) 
on a regular diet are characterized by a markedly lean phenotype. This suggests that 
RAMP1 might exert a protective effect against obesity. To further validate this 
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hypothesis, we challenged the transgenic mice with high-fat diet (HFD). Our findings 
revealed that the lean phenotype is maintained on HFD and the reduction in body 
weight results from increased energy expenditure rather than from a reduction in food 
intake. Hence, RAMP1 appears to be involved in the regulation of energy balance. 
 
Finally, CVOs, such as the AP, have emerged as new neurogenic niches in the adult 
brain, and amylin has been recently shown to exert a neurotrophic effect. Therefore, 
we combined transcriptome analysis and immunohistochemical techniques to 
investigated acute and chronic effects of amylin treatment on the AP of adult rats. Our 
results showed that acute amylin regulates genes involved in multiple pathways and 
processes of adult neurogenesis. Moreover, chronic amylin infusion increases the 
number of newly proliferating cells in the adult AP, and determines the fate-
commitment of these adult-born cells into mature neurons rather than glia.  
 
 
In summary, we demonstrated that all the AMY subunits and the LepRb are co-
expressed in single AP-neurons. Acute amylin administration differentially regulates 
the transcripts of the RAMPs and the LepRb in the AP. Additionally, acute amylin 
affects genes involved in the regulation of multiple pathways and processes of adult 
neurogenesis. Chronic amylin treatment increases the number of newly proliferating 
cells in the AP and determines their neuronal fate over glia. Thus, amylin, in addition 
to its role as a satiating hormone, plays a novel role in the regulation of neurogenic 
processes in the AP of adult rats. 
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2. Zusammenfassung 
 
Amylin, auch bekannt als Insel-Amyloid-Polypeptid, wird zusammen mit Insulin nach 
Nahrungsaufnahme von den pankreatischen ß-Zellen sezerniert. Amylin verringert die 
Nahrungsaufnahme und die Körpergewichtszunahme bei Labortieren; daneben hat es 
auch Charakteristika der sog. Adipositas-Signale und ist an der Steuerung der 
Energieabgabe beteiligt. Das von den ß-Zellen sezernierte Amylin wirkt im zentralen 
Nervensystem und aktiviert dort v.a. Neurone in der sog. Area postrema (AP), einem 
Zirkumventrikulär-Organ (CVO), welches sich im caudalen Hirnstamm befindet. 
Amylin-Rezeptoren (AMY) sind Heterodimere des Calcitonin-Rezeptors, und zwar 
dessen Isoform a (CTRa), und einem sog. Rezeptoren-Aktivität modifizierenden 
Protein (RAMP). Amylin interagiert synergistisch mit dem vom Fettgewebe 
gebildeten Hormon Leptin; eine wichtige Wirkung von Amylin ist, dass es die Leptin-
Resistenz bei Übergewicht reduziert. Wo diese Interaktion stattfindet, ist noch nicht 
genau bekannt; aufgrund früherer Befunde könnte allerdings auch diesbezüglich die 
AP eine wichtige Rolle spielen. Momentan noch unbekannt ist, ob die verschiedenen 
Untereinheiten des AMYs und von Leptin-Rezeptoren (LepRb) in einzelnen AP-
Neuronen ko-exprimiert sind. Im ersten Teil meines Projekts untersuchte ich deshalb 
mittels der sog. laser microdissection an AP-Neuronen die Expression dieser 
Rezeptor-Komponenten auf der Einzelzell-Ebene (single-cell qPCR). Unsere 
Ergebnisse zeigten, dass CTRa und eines oder sogar mehrere RAMPs Transkripte in 
einzelnen AP-Neuronen exprimiert waren. Amylin selbst beeinflusste die Expression 
seines Rezeptors dahingehend, dass die Expression von CTRa unverändert blieb, 
dagegen war die Expression der RAMP1 und RAMP3 mRNAs nach Amylin-
Injektion reduziert. Schliesslich zeigte sich, dass ca. 30% der AP Neurone, die 
funktionelle AMYs besitzen, ebenfalls die mRNA des LepRb exprimierten. Meine 
Untersuchungen zeigten folglich, dass in Zellen, die einen funktionellen AMY 
besitzen, verschiedene Kombinationen von CTRa und RAMP zur Amylin-Funktion 
beitragen können. Welcher Rezeptor-Subtyp genau für welche Amylin-vermittelte 
Wirkung verantwortlich ist, ist allerdings noch nicht bekannt. 
In weiteren Versuchen untersuchte ich speziell die Rolle von RAMP1 bei der 
Vermittlung der Amylin-Wirkung; dazu dienten Mäuse, die die humane Version des 
RAMP1 in Nervenzellen überexprimieren. Die Hypothese war, dass der auf dem 
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RAMP1-Subtyp basierende AMY v.a. eine wichtige Rolle bei der Regulation der 
Energieabgabe spielen könnte. In der Tat hatten diese transgenen Nestin/hRAMP1 
Mäuse ein niedrigeres Körpergewicht als entsprechende Kontrolltiere, was nahe legt, 
dass RAMP1 eine schützende Wirkung gegen Adipositas ausüben könnte. Um diese 
Hypothese zu bestätigen, fütterten wir die transgenen Mäuse auch mit einem Futter 
mit hohem Fettgehalt. Auch diese Mäuse wogen weniger als Kontrolltiere, was v.a. 
auf einer erhöhten Energieabgabe als einer verringerten Nahrungsaufnahme zu 
beruhen schien. Diese Befunde stützen unsere Hypothese, dass RAMP1 bei der 
Regulation der Energiebilanz eine bedeutende Rolle spielt. 
 
Schließlich zeigten meine Untersuchungen, dass in der AP erwachsener Ratten 
laufend neue Nervenzellen gebildet werden, d.h. dass es sich bei der AP um eine sog. 
neurogene Nische zu handeln scheint. Neben einer neurotrophen Wirkung bei 
neugeborenen Mäusen zeigten unsere Ergebnisse, dass Amylin die Expression von 
Genen reguliert, die bei verschiedenen Prozesse der Neurogenese beteiligt sind. Eine 
chronische Amylin Verabreichung erhöhte die Anzahl proliferierender Zellen in der 
AP, bei denen es sich mehrheitlich um Neurone handelte. 
 
Zusammenfassend zeigten meine Untersuchungen, dass alle AMY-Untereinheiten 
und auch der LepRb in einzelnen AP-Neuronen exprimiert sind. Erstmals wurde 
dadurch nachgewiesen, dass auch in nativem Nervengewebe die notwendigen 
Rezeptor-Komponenten ko-exprimiert sind, und die AP deshalb auch direkt an der 
Vermittlung der synergistischen Interaktion von Amylin und Leptin beteiligt sein 
könnte. Weiterhin konnte ich zeigen, Amylin Gene beeinflusst, die an der 
Neurogenese beteiligt sind. Eine chronische Amylin-Behandlung steigerte die Zahl 
der neugebildeten Zellen in der AP, wobei es sich v.a. um Neurone handelte. Neben 
seiner Rolle als Sättigungshormon scheint Amylin deshalb auch eine zuvor 
unbekannte Rolle bei der Regulation neurogene Prozesse in der AP von erwachsenen 
Ratten zu spielen. !
 
 !!
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3. Introduction 
    
 
3.1. The control of food intake and body weight 
 
3.1.1 Energy balance 
Homeostasis (from Greek “homeo”; similar and “stasis”; stable) is defined as the 
property of a system in which variables are regulated so that internal conditions 
remain relatively stable.  Homeostasis, strictly applied to humans, could be translated 
as “Equilibrium”. The maintenance of a personal and healthy equilibrium is an 
everyday challenge. Humans, as with all the other living organisms, depend on energy 
to perform their normal physiological functions and thus to preserve their 
homeostasis. Energy derived from food and the body has fine regulatory mechanisms 
that allow energy absorption, storage and expenditure. To maintain the equilibrium 
the energy acquired from food and beverages intake needs to be balanced by the 
energy expenditure (i.e; basal metabolism, thermogenesis and physical activity; 
Figure 1). 
How the body (and the brain) achieves and maintains energy balance is not 
completely understood.  A complex physiological network is involved. This system 
includes peripheral signals regarding energy stores and signals originating from the 
central nervous system (CNS) that affect energy intake and expenditure (Sandoval et 
al., 2008). Further, all these signals can influence each other and resulting in a 
positive or negative energy balance (Jebb et al., 1996; Leibel et al., 1995).  
The weight of an individual, at least in adulthood, is one of the most stable parameters 
and it is consistent with the physiological control of energy homeostasis. A deep 
understanding of the balance between calories in and energy out would therefore be 
fundamental to reduce, and potentially prevent, obesity. 
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Figure 1: Energy Balance 
 
Illustration describing the maintenance of energy balance. The amount of energy intake (food, 
beverages) and the amount of energy expenditure (basal metabolism, physical exercises) requires 
tightly regulated control mechanisms. http://www.goodtobeyou.nl/calories/. 
 
 
3.1.2 Obesity 
Obesity is defined as abnormal or excessive fat accumulation that involves risks for 
the health status. A crude measurement of obesity is the body mass index (BMI) 
which represents the weight of a person (in Kg) divided by the square of the height (in 
meters). According to the World Health Organization (WHO) a BMI above 25 kg/m2 
defines a person as overweight, while BMI > 30 represents obesity. The worldwide 
prevalence of the disorder in adults more than doubled between 1980 and 2014 and 
currently almost 40% of the population is affected by obesity 
(http://www.who.int/topics/obesity/en/; Figure 2). Of particular concern is the 
associated epidemic of obesity in children and adolescents; up to 2013, forty-two 
million children under 5 years of age were overweight or obese and there is strong 
evidence of persistence into adulthood (WHO, 2014). Overweight and obesity are 
associated with substantial increases in morbidity, premature mortality, impaired 
quality of life and large healthcare costs (Heo et al., 2003; Kopelman, 2000). The 
major adverse comorbidities include cardiovascular disease, type 2 diabetes (T2D), 
!! 11!
metabolic syndrome, gastrointestinal and respiratory difficulties and certain cancers 
(Haslam and James, 2005). Moreover, adiposity and T2D are significantly linked to 
an increased risk of developing the Alzheimer’s disease (AD) (Arvanitakis et al., 
2004; de la Monte and Tong, 2014). 
 
Indeed, obesity is associated with 1 out of 5 deaths among Americans and the illness-
related economic costs are approximately $150 billion per annum (Finkelstein et al., 
2009). Although education of the population to prevent the onset of overweight and 
obesity is a long-term goal, concrete treatment is actively required for those who are 
already obese. Surprisingly, successful treatment options still remain quite limited. 
Changes in lifestyle targeting the everyday diet and the incentive to perform exercise 
per se, unfortunately, do not generally result in marked or sustainable weight loss 
(Dansinger et al., 2005; Phelan et al., 2006), whereas effective psychological 
therapies cannot easily be delivered on a mass scale and long-term results are 
disappointing. Bariatric surgery, such as Roux-en-Y bypass or gastric sleeve, is 
nowadays the most effective treatment in terms of weight loss, comorbidity reduction 
and enhanced survival (Kral and Naslund, 2007). However, the possible surgical 
complications and the overall cost make these bariatric procedures strictly reserved 
for the morbidly obese (Melnikova and Wages, 2006). Hence, obesity still represents 
a major public health problem. Despite the concern regarding individual lifestyles, 
also public health and therefore economics are also affected by the prevalence of 
obesity. Developing effective and long-lasting therapies against obesity appear to be 
of primary importance. To be successful in this fight, a deep understanding of the 
mechanisms that control food intake and energy balance and how they are changed in 
obese individuals is essential. 
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Figure 2: Prevalence of obesity (BMI ≥ 30 kg/m2) in male adults, 2014 
 
World map showing the prevalence of obesity in male aged 18 years old and over. In 2014, more than 
half a billion adults worldwide has been classified as obese.  Red countries, such as the USA, the UK, 
Canada and Australia, have more than 25% of obese individuals. Adapted from WHO, 2014. 
 
 
3.1.3 How obesity affects the brain 
While the consequences of obesity on metabolic and cardiovascular physiology are 
well settled, epidemiological and experimental data are beginning to establish that the 
CNS may also be detrimentally affected by obesity and obesity-induced metabolic 
dysfunction. 
Obesity accelerates the onset of age-related disorders, such as myocardial dysfunction 
(Hubert et al., 1983), hypertension (Stamler et al., 1978) and stroke (Walker et al., 
1996). Therefore, there is a consistent possibility that obesity could also affect aging 
per se and age-related diseases. In the last decade computed tomography and 
magnetic resonance imaging studies in humans reported an altered morphology in the 
brains of obese subjects; in particular, a reduction in the whole brain volume was 
found to be strictly associated with body adiposity (Bruce-Keller et al., 2009; Ward et 
al., 2005). Further evidence showed that in the brain of obese patients the volume of 
the focal grey matter is reduced (reflecting a neuronal loss), while the volume of 
white matter is enlarged (Pannacciulli et al., 2006). Interestingly it has been reported 
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that such structural changes in the brains of obese patients may partially revert with 
dieting (Haltia et al., 2007). Moreover, the degeneration of neuronal pathways 
involved in the onset of neurodegenerative diseases such as AD and Parkinson’s 
disease (PD) may involve compounds (i.e., neuro-peptides) with the ability to cross 
the blood-brain barrier (BBB) that might exert neuro-toxic actions on neurons. 
Hormones like amylin and leptin, which are involved in the control of energy 
homeostasis mainly by reducing food intake and body weight, have the ability to 
cross the BBB (Banks et al., 1995) and might affect the survival of neurons (Doherty, 
2011; Jackson et al., 2013). Reductions in amylin and leptin signaling lead to body 
weight gain and recent studies also report that low plasma leptin levels are associated 
with the onset of AD (Lieb et al., 2009). Plasma amylin levels are also reduced in 
subjects showing signs of mild cognitive impairment and AD (Adler et al., 2014). 
Furthermore, leptin is able to regulate the secretion and uptake of amyloid beta 
peptides in vitro (Fewlass et al., 2004; Greco et al., 2009). Chronic treatment with the 
amylin analogue pramlintide increases synaptic protein expression and cognition in a 
mouse model of AD (Adler et al., 2014). A dysregulation of leptin, amylin and also of 
the hunger-hormone ghrelin might contribute to the advance of metabolic syndromes, 
which are correlated with an increased risk of developing cognitive dysfunction and 
neurodegeneration (Kim and Feldman, 2015; van Dijk et al., 2015). However, those 
hormones and their mimetic compounds have the ability to inhibit apoptotic and 
inflammatory processes and to promote cognitive functions, thus resulting in neuro-
protective responses in the CNS (Folch et al., 2013). Improving the understanding on 
the mechanisms by which obesity affects the brain would notably advance the public 
health and would also help delineate the link between aging, obesity and cognitive 
decline. 
 
 
3.2 The peptide hormone amylin 
 
3.2.1 Amylin synthesis and secretion 
Amylin, also known as “islet amyloid polypeptide (IAPP)”, (hereafter referred to as 
amylin) is a pancreatic peptide hormone. It is co-secreted with insulin by the 
pancreatic β-cells in a molar ratio of approximately 1:100 (amylin:insulin), in 
response to nutrient ingestion (Butler et al., 1990). Amylin plays a role in glycemic 
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regulation by slowing gastric emptying (Young et al., 1995) and promoting satiation 
(Lutz, 2010a), thereby preventing post-prandial spikes in blood glucose levels. 
Amylin is processed from the precursor pro-islet amyloid polypeptide (pro-IAPP, pro-
amylin, pro-islet protein), which is produced in the β-cells and subsequently 
undergoes post-translational modifications including protease cleavage to produce the 
mature peptide amylin (Sanke et al., 1988).  
Amylin shares the regulatory promoter motif with insulin and is be influenced by 
tumor necrosis factor alpha and fatty acids (Cai et al., 2011; Wiersinga et al., 1991). 
Amylin synthesis is also regulated by factors similar to those influencing insulin 
synthesis (i.e; nutrients, incretin hormones, or neural input) (Butler et al., 1990; 
Cooper, 1994; Hoppener et al., 2000). For example, during T2D insulin resistance 
occurs; thus the body does not respond properly to insulin, and this increases insulin 
production. Since pro-insulin and pro-amylin are co-secreted, this results in an 
increase in the production of pro-amylin as well. Following the secretion by the 
pancreatic islets, amylin enters the circulation and it is finally rapidly cleared in the 
kidney (Vine et al., 1998). The half-life of the secreted amylin is therefore ~15 
minutes (Young et al., 1993). Although little is known about amylin regulation, its 
connection to insulin indicates that regulatory mechanisms that affect insulin also 
affect amylin.  
Amylin acts in response to meals by slowing the gastric empting (Young et al., 1995) 
and by inhibiting glucagon secretion (Gedulin et al., 1997). The principal role of 
amylin is its well-described satiation effect, which is achieved by a decrease in food 
intake mainly by reducing the meal size (Lutz et al., 1995). The area postrema (AP) 
seems to be a central site that mediates all the amylin effects (Potes and Lutz, 2010; 
Riediger et al., 2001). Because of all the aforementioned actions, amylin plays a 
necessary and complementary role to insulin, by controlling the flux of nutrients and 
the concentration of postprandial glucose (Rushing et al., 2000b). It is generally 
believed that only the amylin synthetized in the pancreas is responsible for the 
anorectic effect in rodents. Nonetheless, amylin is also produced by other tissues (i.e; 
endocrine cells of the gastric mucosa and sensory neurons of the dorsal root ganglia) 
(Mulder et al., 1995; Mulder et al., 1994). Some evidence exists that amylin might 
also be synthetized in the brain (Skofitsch et al., 1995). However the role of central-
produced amylin is still unknown. Only recently, it has been shown that the amylin 
precursor is centrally expressed in the lateral hypothalamus (LH). Hypothalamic 
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amylin seems to directly act on LH-neurons that carry the leptin receptor in a similar 
manner as the adipokine leptin (Li et al., 2015). Thus, central amylin and leptin 
synergistically interact to regulate long term hypothalamically-mediated feeding 
behavior. Whether amylin synthetized in the CNS has the potential to reach the AP 
and act in concert with the pancreatic amylin to directly stimulate AP-neurons is not 
known yet. 
 
 
3.2.2 Physiological effects of Amylin  
 
3.2.2.1 Amylin acts as a satiation signal 
Amylin’s effect in reducing food intake has been extensively described in rodents and 
humans (Lutz, 2006; Lutz, 2009; Lutz, 2012). Amylin contributes to meal-ending 
satiation, mainly by diminishing meal size (Lutz et al., 1995). Moreover, in the long-
term, administration of amylin decreases food intake and body weight gain in rats.  
Acute intraportal or intraperitoneal (i.p.) injections of amylin (1-100 µg/kg) 
significantly decrease food intake in rodents and dose-dependently reduce meal size, 
without a compensatory increase in meal frequency (Lutz et al., 1994; Lutz et al., 
1995). Moreover, peripheral or central administration of the amylin antagonist AC187 
stimulates eating by increasing meal size (Mollet et al., 2004; Reidelberger et al., 
2004). The lowest dose of exogenous amylin that produces a significant decrease in 
food intake yields plasma amylin levels slightly higher than those measured post-
prandially (Arnelo et al., 1998). Altogether, these findings suggest that amylin is a 
physiological satiation signal. 
Further, amylin chronically infused at high doses (i.e; 50 µg/kg/d) displays a stronger 
eating inhibitory effect in the first few days of infusion compared to later time points 
(Lutz et al., 2001), indicating a decrease in amylin sensitivity. However, our recent 
work showed that when rats are chronically treated with more physiological doses of 
amylin (5-10 µg/kg/d), the animals’ responsiveness to acute amylin injections, and 
thus the decrease in food intake, is maintained over time (Boyle et al., 2011).  
The anorectic effect of peripheral amylin is mediated by a direct humoral action on 
amylin-sensitive neurons in the AP (Lutz et al., 2001). The primary role of the AP in 
mediating the anorectic effect of amylin is strongly supported by behavioral studies 
showing that acute and chronic amylin effects are abolished when the AP and the 
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adjacent parts of the NTS are surgically removed (Lutz et al., 1998b). Further, local 
amylin administration into the AP reduces meal size and the administration of the 
amylin antagonist AC187 has the opposite effect; AC187 also abolishes the eating 
inhibitory effect of peripheral amylin (Mollet et al., 2004). Finally, lesioning of 
noradrenergic AP-neurons has been shown to completely block amylin’s effect on 
eating, indicating an important role of these neurons in mediating the anorectic action 
of amylin (Potes et al., 2010b). Electrophysiological and immunohistochemical 
studies also delineate a direct influence of amylin on AP-neurons (Potes et al., 2012; 
Riediger et al., 2001; Riediger et al., 2004). Moreover, the AP appears to mediate the 
amylin’s action to slow gastric emptying, because ablation of the AP but not of vagal 
afferents blocks this effect (Wickbom et al., 2008; Young et al., 1995).  
 
3.2.2.2 Amylin acts as an adiposity signal 
In addition to its action as satiation signal, several studies indicate that amylin, like 
insulin and leptin, shares the properties of an adiposity signal (Hillebrand and Geary, 
2010; Woods, 2004). In fact, basal plasma levels of amylin are generally higher in 
obese rodent and humans (Pieber et al., 1994), suggesting an association between 
basal plasma amylin and adiposity. Further, chronic amylin administration displays a 
clear effect in reducing body weight gain, specifically by reducing fat mass, in both 
rodents and humans (Arnelo et al., 1996; Mack et al., 2007; Roth et al., 2006). 
Moreover, recent findings describe the effect of central amylin administration in rats 
that were body weight-manipulated by food restriction or overfeeding. Despite the 
food testing conditions, rats centrally injected with amylin show a lower body weight 
compared to controls (Wielinga et al., 2010). Finally, the amylin knockout mouse 
model is fatter compared to its wildtype controls (Lutz, 2006). Therefore amylin, like 
leptin or insulin, appears to be an important signal to maintain a regulated level of 
body weight throughout life.  
 
3.2.2.3 Amylin’s effect on energy expenditure 
Energy homeostasis not only depends on control of energy intake but also on control 
of energy expenditure (EE). Several lines of evidence show that acute and chronic 
amylin administration increases EE in rodents (Mack et al., 2007; Roth et al., 2006). 
First evidence of this phenomenon described a role of the amylin agonist salmon 
calcitonin (sCT) to reduce body weight and body fat mass in fasted rats compared to 
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their controls (Chelikani et al., 2007; Wielinga et al., 2007). Further, several studies 
demonstrated that the fat-mass reduction was greater in rats chronically treated with 
amylin compared to their pair-fed controls. This suggests that amylin is also able to 
increase EE in addition to reduce food intake (Isaksson et al., 2005; Mack et al., 2007; 
Roth et al., 2006; Wielinga et al., 2010). Moreover, acute amylin administration 
directly into the third ventricle or into the AP also increases EE (Osaka et al., 2008; 
Wielinga et al., 2010). Amylin treatment significantly lowers the respiratory exchange 
ratio (RER) in rodents compared to control baseline, reflecting a shift toward lipid 
metabolism. All together these findings suggest that amylin might increase EE via an 
increase in fat oxidation (Rushing et al., 2000a). However, the effect of amylin on the 
reduction of EE might be secondary to the amylin-induced reduction of adiposity or to 
a possible raise in the metabolic activity of the lean mass (Roth et al., 2006). The 
physiological relevance of this amylin effect is not known yet. An open question is 
also which neuronal mechanism mediates this action.  
In this regard, it is important to mention that the sympathetic nervous system plays an 
important role in the regulation of energy metabolism by a direct control on the brown 
adipose tissue (BAT). BAT plays a primary role in the dissipation energy as heat, thus 
contributing to energy expenditure by counteracting weight gain with a thermogenic 
regulation (Seale and Lazar, 2009). Recent studies demonstrate that amylin has the 
potential to increase BAT thermogenic activity (Fernandes-Santos et al., 2013; Zhang 
et al., 2011). Interestingly, double transgenic mice expressing the hRAMP1 
(Nestin/hRAMP1 mice) transgene in the central nervous system show an enhanced 
metabolic response to amylin resulting in a marked reduction of food intake to body 
weight gain ratio, and in an increased body temperature and EE (Zhang et al., 2011). 
Furthermore, the increase in EE is mediated by an augmented sympathetic tone acting 
directly on BAT (Fernandes-Santos et al., 2013; Zhang et al., 2011). The exact 
neuronal mechanisms behind amylin’s action on EE still need to be elucidated. 
 
3.2.3 Amylin receptors  
A functional amylin receptor (AMY) results from a heterodimer of the calcitonin 
receptor (CTR), which belongs to the family of the cell surface bound seven 
transmembrane G protein-coupled receptors (GPCRs), with one member of the single 
transmembrane spanning receptor activity modifying proteins (RAMPs) 
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(Christopoulos et al., 1999). The rat CTR exists in two different isoforms, CTRa and 
CTRb, resulting from an alternate splicing of the CTR gene transcript. The exact 
functional relevance for actions mediated by either the a or the b isoform is not yet 
fully understood. In situ hybridization studies (Barth et al., 2004) that mapped the 
localization of CTRa/b and RAMPs suggest that only CTRa is present in the rat AP 
(Christopoulos et al., 1999; Tilakaratne et al., 2000; Watkins et al., 2014).  
Three members of the RAMP family have been identified (McLatchie et al., 1998; 
Sexton et al., 2001): RAMP1, RAMP2 and RAMP3. They are associated in the 
endoplasmic reticulum and are co-trafficked to the cell surface to form stable 
complexes that act as chaperons to form different receptors with selective ligand 
specificity. The dimerization of RAMP1, RAMP2 and RAMP3 respectively, with 
CTRa, generates AMY1, AMY2 and AMY3 (Alexander et al., 2013; Bailey et al., 
2012) (Figure3). 
 
It has been shown that AMY1 and AMY3 are characterized by high affinities for 
amylin and sCT. However, both receptor types have the potential to bind the 
calcitonin gene-related peptide (CGRP): AMY1 has a 30-fold higher affinity for 
CGRP than AMY3 (Christopoulos et al., 1999), implying that CGRP is most likely to 
target AMY1 rather than AMY3 (Bailey et al., 2012) This suggests that amylin 
predominantly binds to AMY3. While all the RAMPs can generate a functional AMY 
in vitro (Christopoulos et al., 1999; Hay et al., 2004; McLatchie et al., 1998), the 
ability of AMY2 to bind amylin strictly depends on the type of transfected cell line 
and on the CTR isoform (Tilakaratne et al., 2000). In fact, CTRb displays greater 
capacity to dimerize with RAMP2 to generate a functional AMY2 than CTRa (Morfis 
et al., 2008). Because the b isoform of CTR is not present in the AP, it is plausible 
that, in this brain nucleus, RAMP2 mainly couples with the calcitonin-like receptor 
(CLR) to form an adrenomedullin-responsive receptor (ADM) over an AMY2. 
Therefore, different CTR/RAMPs complexes have distinct pharmacology. Further, 
different AMYs might mediate different physiological effects of amylin (e.g, 
satiation, slowing of the gastric empting, reduction of glucagon secretion) and 
discerning which subtype is more relevant to each amylin action is still a challenge. 
 
 
!! 19!
Transgenic mouse models (e.g., RAMPs knockdown) can be instrumental in 
addressing such questions. Moreover, selective viral depletion of CTR in specific 
brain areas leads to obesity in rodents. CTR-ablation in the ventro-medial 
hypothalamus (VMH) of diet-resistant and diet-induced-obese rats on high-fat diet 
(HFD) results in increased body weight, impaired leptin signaling and insulin 
resistance (Dunn-Meynell et al., 2015). Thus, the lack of a fully functional CTR 
signal leads to obesity. Indeed, the core component of the AMY is fundamental to 
mediate the anorectic action of amylin. 
Nestin/hRAMP1 double transgenic mice express the human (h) RAMP1 transgene in 
the CNS (brain, trigeminal ganglion, spinal cord and dorsal root ganglion), thus 
allowing the investigation of the central role of RAMP1. Nestin/hRAMP1 mice are 
characterized by a marked lean phenotype throughout life (Zhang et al., 2011). The 
reduction in body weight results from an increased EE rather than from a decreased 
feeding (Zhang et al., 2011). This suggests that RAMP1 might play a role in the 
regulation of energy balance via a direct effect on EE. However, this study only refers 
to animals maintained on chow. Whether the lean phenotype is preserved also when 
mice are challenged with HFD would shed light on the potential role of RAMP1 to 
prevent obesity. Finally, while RAMP2 knockdown model is not viable, RAMP1 
and/or RAMP3 knockdown are currently available and would be an important tool to 
investigate the different role of each RAMP in vivo. 
Amylin binding sites have been described in the central nervous system (CNS) as well 
in the periphery. Peripheral tissues such as muscle, kidney, lungs, bones, stomach and 
spleen have the potential to bind amylin (Bhogal et al., 1992). The presence of CTR 
and RAMPs have been shown in the AP (Christopoulos et al., 1999; Tilakaratne et al., 
2000; Watkins et al., 2014) and in many different brain areas; such  subfornical organ 
(SFO), organum vaculosum lamina terminalis (OVLT), nucleus accumbens, locus 
coeruleus, dorsal raphe, fundus striatum, nucleus tractus solitarii (NTS), parabrachial 
nucleus (PB), central nucleus of the amygdala, bed nucleus stria terminalis and 
hypothalamic areas: specifically in the nucleus arcuatus (Arc), VMH, and dorso-
medial hypothalamus (DMH) (Becskei et al., 2004; Christopoulos et al., 1995; Le Foll 
et al., 2015; Sexton et al., 1994; Skofitsch et al., 1995). Finally, lately, the mRNA for 
all the components necessary to form a functional AMY have been described in the 
ventral tegmental area (VTA) (Mietlicki-Baase et al., 2015a). However evidence of 
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co-expression of all the AMY subunits in the same cell and in native tissue is still 
missing. 
 
 
 
 
 
 
 
 
 
 
Figure 3: Schematic diagram of the amylin receptors 
Amylin receptors are formed by the interaction of the seven transmembrane calcitonin receptor (CTR) 
with a member of the single transmembrane spanning receptor activity modifying proteins (RAMPs). 
The heterodimerization of CTR with RAMP1, RAMP2 and RAMP3 generates the AMY1, AMY2, 
AMY3 receptors, respectively (Hay et al., 2015). 
 
3.2.4 Central amylin signaling 
The early gene c-fos is a common marker for neuronal activation and its expression is 
used to define brain areas that might be involved in responses to specific stimuli. 
Extensive Fos immunohistochemistry demonstrate that the neuroaxis activated by 
amylin also comprise the NTS and the lateral parabrachial nucleus (LBP) (Becskei et 
al., 2007; Riediger et al., 2004; Rowland et al., 1997). Neuronal tracing studies with 
anterograde and retrograde tracers confirm the direct links between these amylin-
activated areas. These studies also identify the LPB as the primary relay station 
between the hindbrain and the hypothalamus, including the lateral hypothalamic area 
(LHA), where amylin reduces fasting-induced c-Fos expression (Potes et al., 2010a; 
Riediger et al., 2004), and the VMH where histamine H1 receptors may be implicated 
in amylin’s effect on eating (Mollet et al., 2003).  
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Moreover, amylin-induced Fos-response in AP-neurons markedly overlap with 
tyrosine hydroxylase cells; suggesting that the dopaminergic system might also play a 
role in amylin’s inhibitory effect on eating (Potes et al., 2010b). Additionally, amylin 
time and dose-dependently activates the extracellular signal-regulated kinase 1 and 2 
(ERK 1/2) cascade by inducing ERK phosphorylation (Potes et al., 2012). 
Furthermore, the number of pERK-positive AP-neurons is higher 10-15 minutes after 
acute amylin administration, which is the time window in which the satiation effect of 
amylin is at its maximum (Lutz et al., 1995; Potes et al., 2012). The 20% of pERK-
positive AP-neurons are characterized as noradrenergic neurons, showing positivity 
for the dopamine-beta-hydroxylase marker (Potes et al., 2012). Finally, after acute 
amylin stimulus, pERK neurons in the AP partially overlap with the CTR (Potes et al., 
2010b). All these findings support the idea that ERK signaling cascade is employed 
by amylin to induce meal termination in the AP. Further, immunohistological and 
electrophysiological evidence indicates that the amylin’s excitatory effect on AP-cells 
is mediated by an increased formation of cGMP (Riediger et al., 2001). Finally, a 
recent electrophysiological study demonstrates that AMYs are mostly found on 
presynaptic glutamatergic terminals in the AP-neurons, suggesting that glutamatergic 
transmission in the AP might also contribute to mediate the amylin’s effect (Fukuda et 
al., 2013). Despite these findings describing a plausible mechanism of amylin’s 
anorectic action, many questions still remain to be answered to obtain the full picture 
on how amylin signaling is integrated and processed by the brain. 
 
3.2.5 Amylin and leptin interaction 
Amylin is also known to synergistically interact with the adipokine leptin to decrease 
body weight and food intake (Roth et al., 2008; Trevaskis et al., 2010b). Leptin is 
secreted by adipose tissue (Zhang et al., 1994) and regulates energy homeostasis by 
reducing food intake and body weight. The leptin pathway involves a number of brain 
areas, in particular the Arc, the VMH and the NTS in the hindbrain. Leptin influences 
various intracellular signaling cascades in leptin-responsive neurons, including the 
janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) 
signaling cascade (Baumann et al., 1996; Ghilardi et al., 1996; Ihle and Kerr, 1995). 
Physiologically, plasma leptin levels rise in response to fat accumulation in adipose 
tissue, eliciting an anorexigenic response in leptin sensitive individuals (Mainardi et 
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al., 2013). On the contrary, when leptin levels are low all actions are disinhibited: 
food intake increases and energy expenditure decreases. 
It is important to realize that physiologically the sensitivity of the leptin signaling 
system seems to be rather asymmetric. Accordingly, most common forms of obesity 
are associated with high leptin levels and leptin resistance, and further elevations of 
leptin have very little effect. Hence, the system seems to be primed in a way that low 
energy stores lead to a necessary increase in caloric intake (and decrease in energy 
consumption) but that high-energy stores and hence high leptin levels typically cannot 
prevent the development of obesity or reduce obesity once it is established. Several 
studies have shown that the anorexigenic effect of leptin seems to be markedly 
enhanced by amylin (Roth et al., 2008; Trevaskis et al., 2010b; Turek et al., 2010). 
Indeed, several lines of evidence demonstrate that combined treatment of amylin and 
leptin has beneficial effects, the most notably being amylin-induced restoration of 
leptin responsiveness in obese humans and rats (Roth et al., 2008).  
Leptin exerts its effects by binding to the b isoform of the leptin receptor (LepRb), 
and the VMH might be the site mediating the amylin-leptin interaction (Le Foll et al., 
2015; Trevaskis et al., 2010b; Turek et al., 2010). Other brain areas, such as the AP 
(Roth et al., 2008; Trevaskis et al., 2010b) or the VTA (Mietlicki-Baase et al., 2015a) 
may also play a role. A recent electrophysiological study demonstrates that 50% of 
AP-dissociated neurons are excited by both amylin and leptin via an increased cAMP 
intercellular signaling mechanism (Smith et al., 2015). Moreover, previous findings 
demonstrate that pSTAT3 signaling is elevated in the AP in response to leptin (Huo et 
al., 2007). These findings suggest that a neuronal population responsive to both 
amylin and leptin might be present in the AP, however evidence of co-expression of 
AMY and LepRb in individual AP-neurons is still lacking. Understanding the brain 
regions where leptin and amylin interact, and how amylin agonism improves leptin 
sensitivity, would be beneficial to combat leptin resistance and thus to treat obesity. 
 
 
3.2.6 Clinical relevance of amylin and leptin interaction 
 
Several line of evidence demonstrate that amylin and leptin functionally interact to 
reduce food intake and body weight gain, suggesting that the combined treatment with 
amylin and leptin might be helpful to develop anti-obesity drugs. Pair-feeding studies 
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on lean and obese rodents have shown that pharmacological levels of chronic 
peripheral amylin administration (300 µg/kg × d) in diet-induced obesity-prone 
animals is of similar magnitude to that observed in lean animals (Roth et al., 2008). 
Thus, chronic amylin infusion reduces food intake and body fat mass without any 
compensatory decrease in EE (Roth et al., 2008). The amylin analogue pramlintide is 
currently used in the treatment of type 1 and type 2 diabetes mellitus. Pramlintide 
induces weight loss and decreased eating (Chapman et al., 2005). While amylin-
analogue monotherapy is beneficial several studies suggest that the combination of 
amylin and leptin is a very effective treatment against T2D and obesity (Ravussin et 
al., 2009). Co-administration of amylin and leptin has been shown to exert a 
synergistic effect on weight loss. Administration of leptin alone, even at relatively 
high doses, leads to leptin-resistance (Roth et al., 2008). Amylin and amylin agonists 
are able to partially restore leptin responsiveness in obese rodents and humans. The 
synergistic effect results in a fat-specific reduction of weight and this effect might be 
mediated by an amylin-improved leptin signaling in the hindbrain (Ravussin et al., 
2009; Roth et al., 2008). Further studies are still required to define the possible 
outcomes of a prolonged treatment and to evaluate the consequences at the end of the 
therapy. 
 
 
3.3 Adult neurogenesis  
 
3.3.1 Adult neurogenesis in the mammalian brain 
Neurogenesis is defined as the process of generating functional neurons from neural 
stem cells (NSCs) and progenitor cells. It drives nervous system development and is 
mainly active during embryonic and pre-natal stages (Ming and Song, 2005). 
However, in restricted brain areas, neurogenesis still occurs in the adult mammalian 
brain. The first anatomical evidence for the presence of newly generated cells in the 
adult brain was found in the post-natal rat dentate gyrus (DG) (Altman and Das, 
1965). The functional integration of newly generated neurons into the pre-existing 
circuits in the CNS was first shown in songbirds (Paton and Nottebohm, 1984) and 
multipotent NSC were later identified in the mammalian brain (Reynolds and Weiss, 
1992; Richards et al., 1992) 
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Active adult neurogenesis is patterned more in space rather than time. In fact, there 
are two main neurogenic niches in the adult brain: the subgranular zone (SGZ) of the 
hippocampus (Eriksson et al., 1998; Kempermann and Gage, 2000) and the 
subventricular zone (SVZ) lining the lateral ventricle (Doetsch et al., 1999). Newborn 
neurons generated in the SGZ migrate into the granule cell layer of DG, while 
newborn SVZ-neurons migrate along the rostral migratory stream to reach the 
olfactory bulb and become interneurons (Figure 4). However, other brain regions 
might also participate in the generation of new neurons. In fact, adult neurogenesis is 
a dynamic, finely-tuned process which is subjected to modulation by various 
physiological, pathological and pharmacological stimuli. Several lines of evidence 
demonstrate that ischemic injury leads to an increased neurogenesis in the adult 
mammalian brain and this phenomenon might be a source for self-repair (Lin et al., 
2015; Macas et al., 2006). 
The NSCs in the adult brain preserve the ability to self-renew both neurons and glial 
cells (Okano, 2002; Palm et al., 2015). The mechanisms that specify cell fate in adult 
progenitors are finely regulated by extracellular and intracellular programs (Zhao et 
al., 2008) which guide the adult-born cells through proliferation, specification and 
differentiation. When a NSC is destined to become a neuron, the transition from 
proliferation to differentiation is accompanied by an increase in proneural beta helix-
loop-helix (bHLH) factor expression. Specifically the bHLH factors Neurogenin 1 and 
2 and MASH mediate the initial stage of neurogenesis, while the neuronal 
differentiation factor bHLH NeuroD (Gao et al., 2009; Kuwabara et al., 2009) and its 
related gene-family drive final differentiation. Astrocyte fate is mainly guide by the 
activation of cytokines, in particular by the interleukin-6 family together with the 
activation of Notch signaling (Ehm et al., 2010). Not only does the latter promote 
gliogenesis, but it also inhibits neurogenesis. When neurons have migrated to their 
final position and are surrounded by astrocytes to form functional synapses, 
oligodendrocytes begin to differentiate. The sonic hedgehog (Shh) pathway (Favaro et 
al., 2009) is responsible for the activation of the transcriptional factors OLIG1 and 
OLIG2 which are essential to determine the oligodentrocytic fate (Doetsch et al., 
2002). 
Once the newly-formed cell types have reached their final location and fate, they need 
to be integrated into the pre-existing circuits in the adult brain. One critical factor in 
this process seems to be time (Mouret et al., 2008; Tashiro et al., 2006). In both the 
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hippocampus (Tashiro et al., 2007) and the olfactory bulb (Yamaguchi and Mori, 
2005), the activity-dependent survival and integration of newborn neurons is 
restricted to a critical time period. Moreover, in the adult hippocampus, the 
integration of newborn cells appears to be coordinated by a complex neural network. 
Immediate early genes such as c-fos, zif268, arc and homer1a are rapidly induced by 
physiological stimuli and behavioral experience and are involved in the preferential 
incorporation of adult-born neurons into the DG neural network to support spatial 
memory. This process is further regulated by the neurotransmitters glutamate and 
GABA (Mongiat and Schinder, 2011). While the role of glutamate is still 
controversial, GABA is known to play a key role in the control of multiple steps of 
adult neurogenesis. In fact, GABAA-receptors are involved in synaptogenesis and 
plasticity in the adult brain and contribute to proliferation, migration and 
differentiation of adult-born neurons (Fritschy and Panzanelli, 2014). Interestingly, in 
hippocampal slices, acute GABA application increases the expression of the 
transcription factor NeuroD within the SGZ (Tozuka et al., 2005). NeuroD is 
necessary to acquire a neuronal fate in the terminal differentiation stage of the granule 
cells in the DG (Tozuka et al., 2005). Finally, GABA-induced depolarization seems to 
be required for the integration of new neurons into the excitatory neuronal circuits in 
the hippocampus and olfactory bulb (Belluzzi et al., 2003; Tozuka et al., 2005). In 
addition, growing evidence supports the role of Ephrin receptors (EphRs) and their 
ligands in modulating neuronal synaptic structure and its physiological properties 
throughout lifespan (Murai and Pasquale, 2004). In juvenile rodent brains, EphRs 
mainly act as regulators of nervous system development by driving cell-cell 
interactions (Lemke, 1997). In the adult brain, EphRs are expressed in the synaptic 
terminals where they influence synaptic plasticity and the commitment to neuronal 
fate (Murai and Pasquale, 2004). Finally, the level of hippocampal neurogenesis is 
correlated with emotional status suggesting that the integration process highly 
contributes to cognitive functions (Sahay and Hen, 2007). In rodents, stress 
consistently decreases the adult hippocampal neurogenesis while the administration of 
anti-depressant increases it (Malberg et al., 2000). 
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Figure 4: Established neurogenic niches in the adult brain.  
 
(A) Schematic representation of the neurogenic regions in the adult rodent brain: the subgranular zone 
(SGZ) in dentate gyrus (DG) of the hippocampus, and the subventricular zone (SVZ) in the later wall 
of the lateral ventricles. (B) SVZ niche composed of type B1 cells, that corresponds to neural stem 
cells, type C cells that rapidly proliferate and type A neuroblasts, which migrate through the rostral 
migratory stream (RMS) to the olfactory bulb (OB) where they mature into interneurons. (C) 
Neurogenesis in the SGZ. Radial type 1 cells give rise to type 2 cells that differentiate into type 3 
neuroblasts that become immature neurons and then mature into granule neurons that migrate into the 
granule cell layer (Varela-Nallar and Inestrosa, 2013). 
 
 
 
3.3.1 Alternative neurogenic niches: the circumventricular organs  
Neurogenic niches are defined as micro-environments that anatomically house stem 
cells and functionally control their development in vivo. These unique regions are 
characterized by certain cellular components (i.e., endothelial cells, ependymal cells, 
astrocytes, microglia, mature neurons and progeny of adult neural precursors) and 
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morphology (Riquelme et al., 2008). 
Worthy of note is the role of vasculature in the maintenance of the neurogenic niches. 
In SVZ explants from adult rats, increased neuronal differentiation is observed when 
explants are co-cultured with endothelial cells (Leventhal et al., 1999). Dividing cells 
in the adult SGZ are found to be anatomically close to the vasculature, especially 
capillaries (Palmer et al., 2000). Finally, in the adult SVZ, there is a broad network of 
planar interconnected blood vessels (Shen et al., 2008; Tavazoie et al., 2008). These 
findings suggest that extensive vascularity is essential in the neurogenic niches where 
blood-derived cues can gain direct access to adult neural precursors and their progeny.  
Recently, the occurrence of neurogenesis and gliogenesis has also been demonstrated 
in circumventricular organs (CVOs) (Bennett et al., 2009; Hourai and Miyata, 2013; 
Lin et al., 2015). CVOs are midlines structures around the third and the fourth 
ventricles (Figure 5a). They are divided in sensory CVOs, which include the AP 
(Figure 5b), the OVLT, and the SFO; and secretory CVOs, which include the median 
eminence (ME), the subcomissural organ, the posterior pituitary and the pineal gland. 
CVOs are unique in structure and function. They are defined as “windows of the 
brain” because of their ability to directly receive information from the blood supply 
and produce critical brain responses in homeostatic functions (i.e; pH balance, blood 
pressure, temperature, etc.) (Gross and Weindl, 1987; Joly et al., 2007; Roth et al., 
2004). This capacity is a consequence of their unique morphology: their surfaces 
lining the ventricles possess specialized ependymal cells called tanycytes that act as a 
partial cerebrospinal fluid barrier. Moreover, CVOs possess permeable fenestrated 
capillaries and a highly deficient BBB allowing them to access to important 
physiological stimuli. Functionally, they maintain the homeostasis of water balance, 
food intake and day and night rhythm (Barth et al., 2004; Brown, 1992; Mimee et al., 
2013).  
To provide an effective response to homeostatic challenges, adult CVOs have the 
unique capacity to continuously reconstruct their vascular and parenchymal 
architecture (Morita et al., 2015). This structural plasticity plays a functional role in 
the detection of peripheral signals and their full integration by central circuits. 
Particularly, the control of feeding behavior and glucose homeostasis relies on the 
CNS capacity to integrate diverse peripheral signals, including amylin, leptin, insulin, 
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glucagon, ghrelin and glucose, that reﬂect the nutritional and energetic state of the 
organism, as well as its ability to generate responses that can regulate feeding 
behavior, energy expenditure and the metabolic activity of cells.  
In rodents, it has been shown that CVOs express neural stem cell markers, and 
transfected cells from CVOs proliferate and differentiate in vitro and in vivo. 
Interestingly, the ME, OVLT and SFO appear to be able to generate only astrocytes in 
vivo, while the AP is able to give rise to both astrocyte and neurons (Bennett et al., 
2009).  
At present, the functional significance of continuous neurogenesis in the adult CVOs 
is under investigation. Considering the peculiar nature of the CVOs, which place them 
in direct contact with all the substances circulating in the blood-flow, including 
harmful molecules, constitutive neurogenesis could primarily serve as a self-repair 
mechanism. Another potential explanation could be that the generation of new 
neurons is required to control homeostasis and the related physiological functions. In 
fact, it has been recently shown that in the ME, tanycytes from the ependymal zone 
generate new neurons that contribute to the control of food intake (Lee et al., 2012). 
The de novo formation and integration of new neurons into existing brain circuitry is 
part of the spectrum of plastic changes that permit the adult mammalian brain to adapt 
to changing functional demands. However, the exact molecular mechanisms 
underlying adult neurogenesis in CVOs are not yet fully understood.  
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Figure 5: Distribution of the circumventricular organs  
 
(a) Midsagittal section of the rat brain showing the distribution of the circumventricular organs 
(CVOs). SFO, subfornical organ; PG, pineal gland; ME, median eminence; OVLT, organum 
vaculosum lamina terminalis (Lin and Iacovitti, 2015). (b) Detailed coronal section of the rat area 
postrema (AP) and the nucleus of the solitary tract (NTS) (Edelsbrunner et al., 2009) 
a) 
b) 
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3.3.2 Hormones involved in the regulation of food intake and in the maintenance 
of energy balance play an important role in adult neurogenesis. 
Adult neurogenesis is emerging as an important player in brain homeostasis and 
disease. In rodents, the constitutive generation of new neurons fundamentally 
contributes to tissue homeostasis and brain functions. Importantly, the regulation of 
food intake and energy balance relies on the integrity of homeostasis. Hormones that 
controls food intake and energy balance, such as amylin, insulin, ghrelin and leptin, 
seem to have an underappreciated role in adult neurogenesis (Figure 6). 
 
The satiating hormone amylin might also exert a neuro-protective role in the brain 
(Adler et al., 2014). Work from our group showed that neonatal, amylin-deficient 
mice have reduced neuronal projections from the AP to the NTS, suggesting that 
amylin has the potential to function as a trophic factor in the brain (Lutz, 2010b).  
Moreover, in the hippocampus and AP, chronic amylin administration has been 
shown to compensate for the reduction in neurogenesis observed in female 
ovariectomized rats (Trevaskis et al, 2010). Finally, it was also shown that the chronic 
treatment with amylin analogue pramlintide improved memory and cognition and 
ameliorated hippocampal pathology in a mouse model of Alzheimer's disease (Adler 
et al, 2014).   
Amylin is not the only hormone that plays a dual role in regulating feeding behavior 
and neurogenic activity. Insulin is generally known for its role in the control of food 
intake and energy balance. However, insulin also plays important role in cognitive 
functions in the brain, mainly by contributing to the regulation of structural plasticity 
(Chiu et al., 2008). Further, the insulin-like growth factor 1 has the ability to increase 
hippocampal neurogenesis and it can rescue the normal development of dendritic 
processes of immature neurons after brain injuries (Carlson et al., 2014). 
Ghrelin is a neuropeptide hormone released by cells in the gastrointestinal tract (Inui 
et al., 2004; Sakata and Sakai, 2010) which regulates appetite and the distribution and 
rate of use of energy (Burger and Berner, 2014). Ghrelin has the ability to cross the 
BBB and primarily acts on hypothalamic neurons to increase hunger, gastric acid 
secretion and gastrointestinal motility (Schwartz et al., 2000). The ghrelin-mediated 
increase in appetite and fat mass is the result of the activation of a specific neuronal 
population in the Arc (Hewson and Dickson, 2000). Those hypothalamic neurons 
were identified as orexigenic Neuropeptide-Y (NPY) neurons (Dickson and Luckman, 
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1997) and they are responsive to ghrelin as well as to insulin and leptin (Hewson et 
al., 2002; Perello et al., 2012). In addition, ghrelin promotes the proliferation of 
intestinal cells and inhibits apoptosis during inflammatory states and oxidative stress 
in the gastrointestinal tract (Waseem et al., 2008). Despite its role as a hunger 
hormone, ghrelin also plays a role in the hippocampus where it enhances synaptic 
plasticity, adult neurogenesis and the maintenance of long-lasting improvements in 
spatial hippocampal memory (Kent et al., 2015).  
In addition to its role in the control of food intake and body weight, Specifically, 
leptin increases adult neurogenesis in vivo and in vitro by increasing the number of 
proliferating cells, while cell differentiation and survival seem not to be affected by 
leptin treatment (Garza et al., 2008). 
All these studies depict a scenario where food-related hormones may link metabolic 
and cognitive functions. Specifically, amylin, insulin, leptin and ghrelin might 
contribute to the generation and integration of new neurons into pre-existing circuits 
in the adult brain (Figure 5). Therefore, elucidating the underlying mechanism of this 
relationship holds promise to identify modifiable lifestyles factors and novel 
therapeutic targets that might exert beneficial effects not only on the body, but also on 
the brain. 
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Figure 6: Hormones involved in the control of food intake contribute to the regulation of energy 
balance and neurogenesis. 
 
Leptin is produced by adipose tissue, insulin and amylin are co-secreted from the pancreatic β-cells and 
ghrelin is released from the stomach. All these hormones participate in the coordinated regulation of 
food intake and the maintenance of energy balance. Leptin, insulin, amylin and ghrelin also contribute 
to higher cognitive functions. 
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Aims of the project 
 
Aim 1: Identify the co-expression of amylin receptor subunits (CTRa, RAMP1, 
RAMP2 and RAMP3) and the leptin receptor b (LepRb) in single neurons in the 
rat area postrema. 
A functional amylin receptor (AMY) is a heterodimer of the CTRa and one member 
of the RAMP family (RAMP1, RAMP2, RAMP3). The interaction between those two 
subunits has been described above, although the exact cellular location of these 
subunit remains unknown. Therefore, we evaluated the presence of the relative 
expression of these mRNAs in single amylin-activated neurons in the rat AP. To 
further assess the role of the AMY in mediating the leptin’s effects, we also 
investigated the co-expression of the long form of the leptin receptor (Lepr-b) in 
single AP-neurons. 
 
Aim 2: Analyze the transcriptome profiling of the genes differentially regulated 
by amylin in the rat AP. 
Previous findings (Hindmarch et al., 2011) partially describe the pool of genes present 
in the rat AP, but the transcripts differentially regulated by amylin have not been 
investigated and their biological relevance remains unclear. Next-generation 
sequencing allows for a full characterization of the transcriptome of the AP. To 
describe the gene expression of the rat AP, we injected animals with vehicle, amylin 
or with amylin and the amylin antagonist AC187 injections.  
 
Aim 3: Investigate the role of amylin in adult neurogenesis in the rat AP. 
CVOs have been recently described as new “neurogenic niches” in the adult 
mammalian brain. The AP is a well-known sensory CVO which monitors blood-
derived information and relaying this information to other brain regions. 
Neurogenesis and gliogenesis have been demonstrated in the AP in vivo; moreover, 
recently amylin has been shown to promote the formation of neuronal projections 
originating from the neonatal mouse AP. However, the role of amylin in adult 
neurogenesis remains unknown. Here we evaluated the effect of chronic amylin 
infusion on the number of proliferative cells and their cell fates in the AP of adult rats. 
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Aim 4: Characterize the feeding behavior of the Nestin/hRamp1 transgenic 
mouse model which overexpresses RAMP1. 
Previous work (Zhang et al., 2011) demonstrates that Nestin/hRAMP1 double 
transgenic mice are characterized by a marked lean phenotype associated with 
increased EE and normal food intake. This suggests, that the overexpression of 
RAMP1 might exert a protective role against obesity. However, a full characterization 
of feeding behavior in these mice on chow is still missing. Therefore, we monitored 
body weight, food intake, meal patterns, meal size and energy expenditure of 
Nestin/hRAMP1 mice maintained on normal chow. To further assess whether RAMP1 
can protect mice from diet-induced obesity, we also challenged the animals with 
HFD).  
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5. Original Research article: “Amylin receptor components and the 
leptin receptor are co-expressed in single area postrema neurons” 
 
 
This section contains an original research article that was submitted for publication to 
the European Journal of Neuroscience in September 2015 and accepted for 
publication in revised form in December 2015. 
My contribution to this manuscript includes the study design, data acquisition, data 
analysis, data interpretation and drafting and revising the manuscript.  
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Abstract
Amylin is a pancreatic b-cell hormone that acts as a satiating signal to inhibit food intake by binding to amylin receptors (AMYs)
and activating a specific neuronal population in the area postrema (AP). AMYs are heterodimers that include a calcitonin receptor
(CTR) subunit [CTR isoform a or b (CTRa or CTRb)] and a member of the receptor activity-modifying proteins (RAMPs). Here,
we used single-cell quantitative polymerase chain reaction to assess co-expression of AMY subunits in AP neurons from rats that
were injected with amylin or vehicle. Because amylin interacts synergistically with the adipokine leptin to reduce body weight, we
also assessed the co-expression of AMY and the leptin receptor isoform b (LepRb) in amylin-activated AP neurons. Single cells
were collected from Wistar rats and from transgenic Fos-GFP rats that express green fluorescent protein (GFP) under the control
of the Fos promoter. We found that the mRNAs of CTRa, RAMP1, RAMP2 and RAMP3 were all co-expressed in single AP neu-
rons. Moreover, most of the CTRa+ cells co-expressed more than one of the RAMPs. Amylin down-regulated RAMP1 and
RAMP3 but not CTR mRNAs in AMY+ neurons, suggesting a possible negative feedback mechanism of amylin at its own primary
receptors. Interestingly, amylin up-regulated RAMP2 mRNA. We also found that a high percentage of single cells that co-
expressed all components of a functional AMY expressed LepRb mRNA. Thus, single AP cells expressed both AMY and LepRb,
which formed a population of first-order neurons that presumably can be directly activated by amylin and, at least in part, also by
leptin.
Introduction
Amylin, also known as islet amyloid polypeptide, is co-secreted
with insulin by pancreatic b-cells in response to nutrient stimuli
(Lutz, 2010). Amylin reduces food intake and body weight (Lutz
et al., 2001; Roth et al., 2012) and may also act as an adiposity sig-
nal to control energy expenditure (Wielinga et al., 2007; Zhang
et al., 2011). Circulating amylin acts centrally to control the energy
balance by primarily activating neurons of the area postrema (AP), a
circumventricular organ located in the hindbrain (Riediger et al.,
2001, 2004; Lutz, 2009; Potes & Lutz, 2010; Potes et al., 2012).
A functional amylin receptor (AMY) results from a heterodimer
of the calcitonin receptor (CTR) with one member of the receptor
activity-modifying proteins (RAMPs) (Christopoulos et al., 1999).
The rat CTR exists in two different isoforms, CTRa and CTRb, but
the exact functional relevance of action mediated by either isoform
is not yet fully understood. In situ hybridization studies that mapped
the localization of CTRa/b and RAMPs suggested that only CTRa is
present in the AP of rodents (Ueda et al., 2001; Barth et al., 2004).
Three members of the RAMP family have been identiﬁed
(McLatchie et al., 1998; Sexton et al., 2001): RAMP1, RAMP2 and
RAMP3. They are associated in the endoplasmic reticulum and are
co-trafﬁcked to the cell surface in order to form stable complexes
that act as chaperones to form different receptors with selective
ligand speciﬁcity. The dimerization of RAMP1, RAMP2 and
RAMP3 with CTRa generates AMY1, AMY2 and AMY3, respec-
tively (Bailey et al., 2012; Alexander et al., 2013).
The presence of CTR and RAMPs has been shown in different
brain areas (Sexton et al., 1994; Christopoulos et al., 1995; Sko-
ﬁtsch et al., 1995; Becskei et al., 2004; Mietlicki-Baase et al.,
2013). However, none of these studies tested the co-localization of
the AMY components at the single-cell level, which is necessary to
study the physiological relevance of CTR and RAMPs in vivo.Correspondence: Christina Neuner Boyle, as above.
E-mail: boyle@vetphys.uzh.ch
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Amylin is also known to synergistically interact with leptin to
decrease body weight and food intake (Roth et al., 2008; Trevaskis
et al., 2010). Leptin exerts its effects by binding to the leptin recep-
tor isoform b (LepRb), and the ventromedial nucleus of the hypotha-
lamus may be the site mediating the amylin–leptin interaction
(Trevaskis et al., 2010; Turek et al., 2010; Le Foll et al., 2015).
Other brain areas, such as the AP (Roth et al., 2008; Trevaskis
et al., 2010) or ventral tegmental area may also play a role (Mie-
tlicki-Baase et al., 2015); however, a population of ﬁrst-order neu-
rons bearing receptors for both amylin and leptin has yet to be
reported (Turek et al., 2010; but see Smith et al., 2015). Evidence
of single neurons expressing both hormone receptors is lacking.
To establish that all components of the AMY are present in single
AP cells and to investigate whether AP neurons co-express AMY
and leptin receptors, we examined the mRNA expression of CTRa
and RAMPs in single AP cells, and of LepRb in AMY+ neurons.
Materials and methods
Animals and tissue collection
Male Wistar rats (Janvier, Le Genest Saint Isle, France) (Experi-
ments 1 and 2; 200–225 g) and male and female Fos-GFP rats
(NIDA/NIH; Baltimore, MD, USA and NIMH/NIH; Bethesda, MD,
USA) (Experiments 3–5; 250–320 g) were single-housed in a tem-
perature-controlled environment (21 ! 1 °C) on an artiﬁcial 12-h/
12-h light/dark cycle. Rats had ad libitum access to water and stan-
dard chow, except during fasting periods as described below. All
procedures involving animals and their care were approved by the
Veterinary Ofﬁce of the Canton Z€urich, Switzerland, and were in
accordance with the EU Directive 2010/63/EU on the protection of
animals used for scientiﬁc purposes.
Drugs
Amylin (Bachem AG, Bubendorf, Switzerland; catalogue no. H-
9475.1000) was reconstituted with sterile 0.9% NaCl.
Experimental design
Rat injections and sample preparation
For all experiments, rats were fasted for 12 h and injected i.p. with
vehicle or amylin (20 lg/kg for Wistar rats and 50 lg/kg for Fos-
GFP rats) at dark onset. At 90 min after drug administration, rats
were anaesthetized with isoﬂurane and decapitated.
Experiment 1
Brains from Wistar rats (n = 4) were promptly processed under a
light microscope. The AP was surgically removed from the brain-
stem and then the subfornical organ (Takahashi et al., 1997) and
hypothalamus were dissected. All of the tissues were placed imme-
diately in TRI Reagent! (Sigma-Aldrich) and processed for reverse
transcription-polymerase chain reaction, as described below.
Experiments 2–5
Brains were rapidly isolated, snap-frozen in cold isopentane and
embedded in Tissue-Tek! OCTTM (Sakura Finetek) compound just
prior to sectioning. Coronal sections were cut at 10-lm thickness on
a cryostat (Leica, Germany) through the entire AP and afﬁxed on
precleaned, Superfrost glass slides (Thermo Scientiﬁc, Waltham,
MA, USA). The sections were immediately placed in a slide box on
dry ice until completion of sectioning. The slide box was rinsed
with RNase Away (Molecular BioProduct, Mexico) prior to usage to
prevent RNA degradation. Samples were then stored at "80 °C
until the laser capture microdissection (LCM) procedure.
In Experiment 2, Wistar rats (n = 4/group) were treated with
amylin (20 lg/kg, i.p.) and single neurons (n = 8–10 cells/rat) were
identiﬁed with cresyl violet staining as previously described (Kadar
et al., 2009). CTRa, RAMP1 and RAMP3 have been extensively
described as being present in the rat AP (Becskei et al., 2004), thus
generating AMY1 and AMY3 as the primary AMYs in this brain
nucleus. RAMP2 mainly contributes to the generation of AMY2 by
coupling with CTRb (Tilakaratne et al., 2000). Because CTRb is
not expressed in the rat AP (Ueda et al., 2001; Barth et al., 2004),
we mainly focused on the analysis of RAMP1 and RAMP3 in com-
bination with CTRa.
In Experiments 3–5, Fos-GFP transgenic male and female rats
(n = 4 rats/treatment/gender) were treated with vehicle or amylin
(50 lg/kg, i.p.). Fos-GFP rats express the green ﬂuorescent protein
(GFP) under the Fos promoter in strongly activated neurons (Cifani
et al., 2012) and therefore no additional immunohistochemical pro-
cedure was required to visualize Fos-GFP-activated neurons. Amy-
lin-stimulated cells (n = 9–10 cells/rat) were readily detectable
under the enhanced GFP (eGFP) ﬁlter (490–560 nm).
Reverse transcription-polymerase chain reaction
RNA was extracted according to the manufacturer’s instructions
(TRI Reagent!, Sigma-Aldrich) and then puriﬁed following the
clean-up protocol of the RNeasy! Mini kit (Qiagen, Germany),
including the DNase step. The concentration and integrity of RNA
were measured using a nanodrop system (NanoDrop 1000 Spec-
trophotometer, Thermo Scientiﬁc). cDNA was generated from the
extracted RNA using the Terto cDNA synthesis kit (Bioline,
Switzerland).
The primer pairs for rat CTRa/b were reported previously (Mori
et al., 2006) and the primers for rat glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) were manually designed using Primer 3
web version 3.0.0. The primer sequences for rat CTRa/b were as
follows: forward: 5ʹ-TGGTTGAGGTTGTGCCCAATGGA-3ʹ and
reverse: 5ʹ-TCCATGGGTTTGCCTCATCTTGGTC-3ʹ. This primer
pair was able to differentiate the two isoforms of CTR, giving a
392-bp product for CTRa and a 503-bp product for CTRb (Acces-
sion no. L14617 and L13040). For rat GAPDH the primer
sequences were as follows: forward: 5ʹ-GCCAGCCTCGTCTCATA
GACA-3ʹ and reverse: 5ʹ-GTGCGATACGGCCCAATC-3ʹ (Acces-
sion no. NM_017008.4). The reverse transcription-polymerase chain
reaction conditions were as follows: initial denaturation for 3 min at
95 °C, followed by 35 alternating cycles of 15 s at 95 °C and 15 s
at 60 °C, and a ﬁnal extension step of 20 s at 72 °C. The reverse
transcription-polymerase chain reaction ampliﬁcation products were
separated by 2% agarose gel electrophoresis (3000 Xi, BioRad).
Laser capture microdissection
Slides containing AP sections, collected from Wistar rats and vehi-
cle-treated Fos-GFP animals, were Nissl stained to allow cell identi-
ﬁcation. Slides were removed from "80 °C and thawed at 4 °C for
2 min, and sections were stained in 0.1% cresyl violet acetate
(Sigma-Aldrich) solution dissolved in 70% ethanol for 5 min on ice.
The excess stain was drained on ﬁlter paper. Sections were then
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dehydrated once in 96% EtOH and once in 100% EtOH, for 30 s
each, on ice, and ﬁnally dried in a fume hood for 2 min at room
temperature (21 ! 1 °C) before being processed under the LCM
microscope (Arcturus X MDS, Life Technologies, Carlsbad, CA,
USA). As described above, no additional immunohistochemical pro-
cedure was required to identify Fos-GFP+ cells in Fos-GFP trans-
genic rats. Brain slices were observed under the microscope and the
AP was localized based on morphology (Bregma "13.68 to
"14.28 mm; Paxinos & Watson, 2007).
In Wistar rats and vehicle-treated Fos-GFP rats, single cells were
visualized with Nissl staining, randomly selected and individually
collected in caps (CapSure! HS LCM caps, Arcturus Bioscience).
In amylin-treated transgenic rats, single Fos-GFP+ cells were identi-
ﬁed under the eGFP ﬁlter and collected in individual caps. Total
RNA was extracted and isolated, including a DNase step, using the
vendor’s protocol (PicoPureTM RNA isolation kit, Arcturus Bio-
science) and subsequently stored at "80 °C.
Quantitative polymerase chain reaction
RNA extracted from each individual cell was ampliﬁed using Ribo-
SPIA technology (Ovation One-Direct System, part no. 3500;
NuGEN, San Carlos, CA, USA) and cDNA was subsequently
puriﬁed using Agencourt RNAClean XP beads. A post-SPIA modiﬁ-
cation process was run to complete the process and to generate
sense-target cDNA, according to the manufacturer’s instructions.
Single-cell quantitative polymerase chain reaction was performed
using the 7500 Fast system (Applied Biosystem/Life Technologies)
with the QuantiTect! SYBR! green polymerase chain reaction kit
(Qiagen). Rat GAPDH was used as the housekeeping gene. To
avoid the possibility of amplifying contaminating DNA, intron-span-
ning primer pairs for rat CTRa, RAMP1 and RAMP3 were designed
with Primer 3 web version 4.0.0. The primer sequences were as fol-
lows: for rat GAPDH, forward: 5ʹ-AGACAGCCGCATCTTCTTGT-
3ʹ and reverse: 5ʹ-CTTGCCGTGCGTAGAGTCAT-3ʹ (Accession no.
NM_017008.4); for rat CTRa, forward: 5ʹ-TTTCCAGGGATTCT
TTGTCG-3ʹ and reverse: 5ʹ-TTCGTTGCTGACTGGAG-3ʹ (Acces-
sion no. NM_001034015.1); for rat RAMP1, forward: 5ʹ-GGCAAA
CAAGATTGGCTGTT-3ʹ and reverse: 5ʹ-AATGGGGAGCACAAT
GGAAG-3ʹ (Accession no. NM_031645.1); for rat RAMP2, primer
pairs were previously reported by Qi et al. (2003), forward:
5ʹ-TGAGGACAGCCTTCTGTCAA-3ʹ and reverse: 5ʹ-CATCGCCG
TCTTTACTCCTC-3ʹ (Accession no. NM_031646.1); and for rat
RAMP3, forward: 5ʹ-AGGTCATCTGGAAGGTGTGG-3ʹ and
reverse: 5ʹ-AATGGGGAGCACAATGGAAG-3ʹ (Accession no.
NM_02100.2). The intron-spanning primer pairs for rat LepRb were
designed with Integrated DNA Technologies as follows: forward:
5ʹ-GGTTGGATGGACTAGGGTATTG-3ʹ and reverse: 5ʹ-CAGAAT
TCAGGCCCTCTCATAG-3ʹ (Accession no. NM_012596.1).
A total of 200 ng of cDNA was subjected to an initial heat acti-
vation at 95 °C for 15 min, followed by 40 cycles alternating
between 94 °C for 15 s and 60 °C for 30 s, and ﬁnal extension at
72 °C for 30 s. The relative transcriptional levels of CTRa, RAMP1,
RAMP2, RAMP3 and LepRb mRNA were calculated using the
comparative DDCt method that generates relative CTRa, RAMP1
and RAMP3 mRNA levels adjusted for the GAPDH endogenous
control mRNA. Each sample was run in duplicate.
Statistical analysis
The CTRa+ cells vs. CTRa" cells (n = 4 rats, 8–10 cells/rat) and
the related presence or absence of RAMPs, respectively, were
analysed with the Chi-squared test (Experiment 2). Relative mRNA
expression levels were assessed by unpaired Student’s t-test (Experi-
ment 4: n = 4 rats, 9–10 cells/rat; Experiment 5: n = 4 rats, 8–10
cells/rat) by using GRAPHPAD software version 5.0 (San Diego, CA,
USA).
Results
Experiment 1: only the CTRa isoform was expressed in native
rat area postrema tissue
Conﬁrming previous studies (Hilton et al., 1995; Barth et al.,
2004), we observed that only the CTRa isoform was expressed in
native rat AP tissue (Fig. 1). The subfornical organ and hypotha-
lamus were used as positive controls, with both brain regions
expressing CTRa and CTRb isoforms (Becskei et al., 2004; Mori
et al., 2006).
Experiment 2: randomly collected cells from the area
postrema of amylin-treated rats presented a complex neuronal
landscape. Most of the CTRa+ cells were RAMP1+ and
RAMP3+, whereas most of the CTRa" cells were also
RAMP1" and RAMP3"
The rapid Nissl staining procedure before LCM enabled the iden-
tiﬁcation of individual cells in the AP sections of amylin-treated
Wistar rats (Fig. 2a). Cells were randomly selected and individu-
ally collected by LCM (Fig. 2a, inset). A presence/absence assay
was performed in which GAPDH was used as the endogenous
control and the analysed neuronal population was divided into
CTRa+ and CTRa" cells, respectively. The resulting neuronal
landscape showed a complex scenario (Fig. 2b). Almost 40% of
the collected neurons were CTRa+ cells; importantly, all CTRa+
cells co-expressed CTRa and RAMP1 (3%), CTRa and RAMP3
(10%) or CTRa and both RAMP1 and RAMP3 (25%); 62% of
the randomly collected cells were CTRa". Moreover, most of the
CTRa" cells were also RAMP1" and RAMP3" (53%); only 9%
of CTRa" cells showed either RAMP1 (6%) or RAMP3 (3%)
expression. Hence, RAMP1 and RAMP3 mRNAs were preferen-
tially expressed in CTRa+ vs. CTRa" cells [Chi-squared test
(30.13, 3), P < 0.0001]. The key ﬁnding of this study was that
CTRa+ cells co-expressed RAMP1 and/or RAMP3 transcript,
which are the necessary subunits required for a speciﬁc and func-
tional AMY1 or AMY3.
Fig. 1. Reverse transcription-polymerase chain reaction showing the distri-
bution of CTR isoforms in different brain nuclei. Agarose gel electrophoresis
of CTRa (392 bp) and CTRb (503 bp) polymerase chain reaction products
from rat AP, subfornical organ (SFO) and hypothalamus (HYP). GADPH
(207 bp) was used as the reference gene and run in different lanes. Only the
CTRa is detected in the rat AP.
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Experiment 3: CTRa, RAMP1 and RAMP3 mRNAs were all
co-expressed in the same single amylin-activated area
postrema neurons of Fos-GFP rats
Results from Experiment 2 clearly showed that, in the neuronal pop-
ulation deﬁned as CTRa+, single cells co-expressed RAMP1,
RAMP3 or both RAMP1 and RAMP3 mRNAs in addition to CTRa.
We reasoned that only this pool of cells expressed a biologically
functional AMY1 or AMY3 and therefore could be activated by
amylin. To test this hypothesis, we combined the use of Fos-GFP
transgenic rats and single-cell quantitative polymerase chain reaction
to better characterize the transcripts of CTRa, RAMP1 and RAMP3
in amylin-activated individual neurons.
Transgenic rats were treated with vehicle or amylin (Fig. 3a and
d, respectively). In the control group, single cells were visualized
with Nissl staining and randomly collected. Results obtained from
the randomly collected single cells treated with vehicle replicated
the scenario of Experiment 2; we conﬁrmed that CTRa! cells were
also generally RAMP1! and RAMP3! (50% of all cells investi-
gated in male rats and 33% in female rats, respectively), whereas
CTRa+ cells were also RAMP1+, RAMP3+ or both RAMP1+ and
RAMP3+ (see Fig. 3b and c for the detailed distribution in male
and female rats, respectively). Amylin treatment induced strong Fos-
GFP expression in the AP (Fig. 3d), allowing the speciﬁc collection
of single amylin-activated neurons. In male rats, 64% of the cell
population showed co-expression of CTRa, RAMP1 and RAMP3 in
the same single neuron; 9% of the collected single neurons co-
expressed CTRa with either RAMP1 (1%) or RAMP3 (8%). Only
27% of the neuronal population expressed one of the RAMPs but
not the CTR (for details, see Fig. 3e). Results obtained from female
transgenic rats displayed a pattern that was similar to the males. In
the amylin-treated female rats, the entire population of amylin-
responsive cells showed co-expression with CTRa and RAMPs;
70% of the collected single cells were CTRa+, RAMP1+ and
RAMP3+, whereas the remaining 30% showed co-expression of
CTRa with either RAMP1(10%) or RAMP3 (20%) (Fig. 3f).
Experiment 4: amylin down-regulated RAMP1 and RAMP3
transcripts in single area postrema neurons, whereas RAMP2
mRNA was up-regulated
To provide an absolute quantiﬁcation of the expression levels of the
mRNAs of CTRa and RAMPs, we selected all of the CTRa+ cells
and compared the relative expression of RAMP1, RAMP2 and
RAMP3 in control-treated and amylin-treated Fos-GFP transgenic
rats. RAMP2 mRNA was also included in this experiment to test
speciﬁcally if identiﬁed CTRa+ cells also expressed RAMP2, in
addition to RAMP1 and RAMP3.
Our ﬁndings demonstrated that, whereas CTRa expression seemed
to be unaffected by acute amylin treatment (t79 = 0.3573,
P = 0.3573), RAMP1 and RAMP3 mRNAs were down-regulated in
amylin-activated single neurons (RAMP1: t62 = 5.409, P < 0.0001;
RAMP3: t67 = 6.640, P < 0.0001; Fig. 4b and d). Interestingly,
amylin up-regulated RAMP2 mRNA in single AP cells (t34 = 3.832;
P < 0.0001, Fig. 4c). See Table 1 for Cycle Threshold (CT) values.
To evaluate the co-expression of RAMP2 mRNA relative to
RAMP1 and RAMP3, a presence/absence analysis was performed in
all CTRa+ cells. In vehicle-treated animals, 70% of single CTRa+
AP neurons expressed RAMP2+ in addition to RAMP1 (2%),
RAMP3 (13%) or both RAMP1 and RAMP3 (55%; Fig. 5a); none
of the CTRa+ cells expressed only RAMP2. The RAMP2 mRNA
distribution was relatively similar in amylin-treated animals (for
details, see Fig. 5b). These ﬁndings provide additional information
on the distribution of RAMP2 mRNA relative to the other RAMPs.
Experiment 5: 30% of amylin-treated single area postrema
neurons that co-expressed all of the necessary components to
form a functional amylin receptor also co-expressed LepRb
mRNA
The presence of LepRb mRNA was investigated in the rats from
Experiment 3 in single cells that were found to express all of the
necessary components to form a functional AMY (CTRa+ and either
individual or combined RAMPs were deﬁned as AMY+). Single
AMY+ cells from both vehicle-treated and amylin-treated groups
were analysed. Under vehicle conditions, 52% of single AMY+ cells
also co-expressed LepRb mRNA (Fig. 6a). In rats treated with amy-
lin, 30% of the AMY+ single cells also co-expressed LepRb
(Fig. 6b). Interestingly, the relative mRNA level of LepRb in
AMY+ cells was signiﬁcantly up-regulated by amylin treatment
(t9 = 2.286, P < 0.05; Fig. 6c; see Table 1 for CT values).
Discussion
The CTR and RAMPs generate receptors with high afﬁnity for amy-
lin (Christopoulos et al., 1999), with the precise nature of these
Fig. 2. Distribution of CTR, RAMP1 and RAMP3 mRNAs in single cells of amylin-treated rats. (a) Nissl staining of rat AP at 20 9. Representative image
showing the LCM laser (blue cross) in the act of collecting a single neuron (red circle with number 1). The green circle represents the ultraviolet laser cutting
spot. Scale bar in inset: 12.5 lm. (b) In randomly picked individual neurons (n = 8–10 cells/rat) from the AP of amylin-treated (20 lg/kg) male Wistar rats
(n = 4), 38% of individual neurons are CTRa+ [25% co-express CTRa and both RAMP1 and RAMP3; 3% co-express CTRa and only RAMP1 and 10% co-
expressed CTRa and only RAMP3]. The remaining 62% of the randomly collected single cells are CTRa!; most of the CTRa! cells are also RAMP1! and
RAMP3! (53%); 6% of all cells are CTRa!, RAMP1+ and RAMP3!, and 3% of all cells are CTRa!, RAMP1! and RAMP3+. RAMP1 and RAMP3 tran-
scripts are preferentially expressed in CTRa+ vs. CTRa! neurons. Chi-square test, P < 0.001. 4 V, fourth ventricle.
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receptors depending on the CTR splice variant and the cellular back-
ground. In the present study we provide evidence that the mRNA
for all components of the AMY complex is co-expressed in the
same single neurons in the rat AP, suggesting intracellular interac-
tions between these subunits to mediate amylin signalling in the
brain. This is the ﬁrst demonstration in native tissue of single cells
expressing all components of the functional AMY that allows them
to be activated directly by amylin. We conﬁrmed that only the
CTRa isoform of the CTR is expressed in the AP; therefore, the
AMY complex in this brain nucleus results from a dimer of one or
more RAMPs exclusively with CTRa (Barth et al., 2004; Becskei
et al., 2004).
By applying the LCM technique, we were able to fully character-
ize the presence of functional AMY at the single-cell level. Our
results indeed support a scenario where in basal conditions AP neu-
rons stochastically express zero, one, two, three or four components
of the AMY. However, only the neurons that concurrently express
CTRa and at least one of the RAMPs bear a functional AMY, and
therefore have the full potential to be directly activated by amylin.
Previous ﬁndings demonstrated that RAMP1, RAMP2 and
RAMP3 all interact with CTRa and CTRb to generate functional
AMY1–3 in vitro (McLatchie et al., 1998; Christopoulos et al.,
1999; Hay et al., 2004). Different CTR/RAMP complexes have dis-
tinct pharmacology, which may determine the rate of amylin binding
to a speciﬁc AMY subtype. AMY1 and AMY3 have high afﬁnities
for amylin and salmon calcitonin and both have the potential to bind
the calcitonin gene-related peptide. However, AMY1 has a 30-fold
higher afﬁnity for calcitonin gene-related peptide than AMY3 (Chris-
topoulos et al., 1999), implying that calcitonin gene-related peptide
is most likely to target AMY1 rather than AMY3. It is important to
mention that, in particular, the ability of RAMP2 to form functional
AMY2 is clearly dependent on the cellular background and on the
receptor isoform (Tilakaratne et al., 2000). In fact, CTRb displayed
greater capacity to dimerize with RAMP2 to generate a functional
AMY2 than CTRa (Morﬁs et al., 2008). Given that CTRb is not
present in the AP, our work mainly focused on the characterization
and co-expression of CTRa, RAMP1 and RAMP3.
Our ﬁndings showed that, in both male and female rats, the
majority (over 60%) of the amylin-activated, Fos-GFP+ single cells
co-expressed CTRa, RAMP1 and RAMP3 and a smaller percentage
co-expressed CTRa and either RAMP1 or RAMP3. This suggests
that amylin mainly activates cells that express mRNA for CTRa,
RAMP1 and RAMP3. When CTRa was co-expressed with only one
of the RAMPs, the accessory subunit was preferentially RAMP3
(for details, see Fig. 3e and f), suggesting that AMY3 might be the
primary AMY at the cellular level for AP-mediated amylin actions.
The preferential expression of CTRa with RAMP1 and/or RAMP3
in these activated cells also supports the idea that AMY1 and AMY3
are the most physiologically relevant receptors mediating amylin
actions in the AP, and indicates that both subtypes can be present in
Fig. 3. Analysis of single cells captured from vehicle and amylin-treated Fos-GFP rats. AP sections of Fos-GFP rats. (a) Vehicle-treated male rats (n = 4/
group/gender). (b) The randomly collected single cells (n = 9–10 cells/rat) show a mixed distribution: 30% of the single cells were CTRa+/RAMPs+; speciﬁ-
cally 10% were CTRa+/RAMP1+/RAMP3+, 17% were CTRa+/RAMP1+/RAMP3! and 3% were CTRa+/RAMP1!/RAMP3+. In the remaining cell popula-
tion, 50% of the neurons were CTRa!/RAMP1!/RAMP3!, 11% were CTRa!/RAMP1+/RAMP3! and 9% were CTRa!/RAMP1!/RAMP3+. (c) In Fos-
GFP female rats, the results in the vehicle-treated group were consistent with what was shown in males, i.e. 50% of the collected single cells were CTRa+/
RAMPs+; speciﬁcally, 17% were CTRa+/RAMP1+/RAMP3+, 27% were CTRa+/RAMP1+/RAMP3! and 6% were CTRa+/RAMP1!/RAMP3+. The remaining
cell population was characterized as CTRa!, 33% being CTRa!/RAMP1!/RAMP3!, 10% being CTRa!/RAMP1+/RAMP3! and 7% being CTRa!/
RAMP1!/RAMP3+. (d) Amylin-induced Fos expression in AP neurons. The inset shows examples of single amylin Fos-GFP activated cells (scale bar:
10 lm). The green circle represents the ultraviolet cutting spot. (e) In Fos-GFP male rats, the 73% of neurons that showed Fos-GFP expression after amylin
injection (50 lg/kg) were CTRa+. Most of the CTRa+ cells (64%) co-expressed the mRNA of CTRa, RAMP1 and RAMP3, 1% were CTRa+/RAMP1+/
RAMP3! and 8% were deﬁned as CTRa+/RAMP1!/RAMP3+. The remaining neuronal population was characterized as CTR!/RAMP1+/RAMP3! (9%) and
CTR!/RAMP1!/RAMP3+ (18%). (f) In amylin-treated Fos-GFP female rats, all Fos-GFP activated neurons were CTRa+/RAMPs+; 70% of the population
co-expressed CTRa, RAMP1 and RAMP3 in the same single cell, and the remaining 30% co-expressed CTRa and RAMP1 (10%) or CTRa and RAMP3
(20%). 4 V, fourth ventricle.
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individual AP neurons. In Fos-GFP male animals, 27% of amylin-
activated, Fos-GFP+ neurons were characterized as CTR! but
expressed either RAMP1 (9%) or RAMP3 (18%). It is unlikely that
these cells were directly activated by amylin but, because they
expressed GFP after amylin administration, they possibly represent
second-order neurons.
The congruent results obtained in males and females suggest that
the sex of the rat does not seem to be an important factor inﬂuenc-
ing the genetic expression of the components of the AMY. How-
ever, sex hormones may still inﬂuence the relative expression of the
AMY components. Oestradiol strongly up-regulates the mRNA
levels of RAMP3 in the rat uterus (Watanabe et al., 2006), but there
have been no investigations into whether oestradiol may have simi-
lar effects in the brain. Interestingly, our previous work indicates
that oestradiol-treated ovariectomized rats demonstrate enhanced
suppression of eating after acute amylin (Asarian et al., 2011), sug-
gesting that amylin sensitivity ﬂuctuates over the course of the
oestrous cycle, which could in part be the result of oestrogen-
induced changes in RAMP expression.
We also provide evidence that RAMP2 mRNA is co-expressed
with both RAMP1 and RAMP3 transcripts in over 50% of single
AP cells; this highlights the possibility of co-expression of all three
RAMPs along with CTRa in individual AP neurons. However, none
of the individually collected AP neurons co-expressed CTRa and
only RAMP2 mRNA; either one or both RAMP1 and RAMP3 tran-
scripts were co-expressed with RAMP2 in single CTRa+ AP cells.
These results further support the notion that amylin acts predomi-
nantly via AMY1,3 in the AP, rather than AMY2.
It is difﬁcult to know at present whether these different AMYs
have different physiological relevance; further studies are required to
investigate the contribution of AP neurons carrying single vs. multi-
ple RAMPs, in addition to the CTRa (i.e. CTRa/RAMP1, CTRa/
RAMP3, CTRa/RAMP1/RAMP3 or CTRa/RAMP1/RAMP2/
RAMP3 AMYs), to the binding and physiological effect of amylin.
Our current work does not discern whether different variations of
the AMY complex might contribute to the discrete physiological
actions of amylin, such as the control of eating, increase in energy
expenditure, slowing of gastric emptying or inhibition of glucagon
secretion, all of which seem to be AP-mediated effects (Lutz, 2012;
Hay et al., 2015). Knockout or knockdown models of either one or
more RAMPs would be an interesting experimental approach to
answer such questions.
Fig. 4. Effect of amylin on the transcriptional expression of CTRa, RAMP1,
RAMP2 and RAMP3 mRNAs in AP single cells. In Fos-GFP female rats
(n = 4/group), AP single neurons (n = 9–10 cells/rat), which showed co-
expression of CTRa and RAMPs in both vehicle-treated and amylin-treated
animals, were analysed by quantitative polymerase chain reaction. mRNA
expression is shown as fold change; rat GAPDH was used as the housekeep-
ing gene to normalize the data. (a) CTRa mRNA levels were unaffected by
the experimental condition, whereas (b) RAMP1 and (d) RAMP3 transcripts
were signiﬁcantly down-regulated in amylin-treated animals compared with
control-treated rats (RAMP1, ****P < 0.001; RAMP3, ****P < 0.001). (c)
Amylin up-regulated RAMP2 mRNA compared with control
(***P < 0.001); Data shown as mean + SEM.
Table 1. CT values in single AP neurons following vehicle or amylin treatment
Vehicle Amylin
Target Average " SEM Minimum Maximum Average " SEM Minimum Maximum
GAPDH 27.88 " 0.55 26.88 34.96 27.30 " 0.03 26.94 27.52
CTR 29.56 " 0.59 28.14 37.30 29.13 " 0.05 28.79 29.49
RAMP1 30.23 " 0.44 28.96 36.79 32.03 " 0.13 31.00 33.18
RAMP2* 33.32 " 0.39 30.10 36.13 31.69 " 0.95 24.80 37.98
RAMP3 26.79 " 0.48 25.77 32.95 29.12 " 0.05 28.65 29.68
LepRb 32.30 " 0.73 30.40 37.01 27.58 " 0.41 26.12 30.35
*RAMP2 was analysed in a separate experiment in which the GAPDH CT values were: vehicle, 31.74 " 0.93 (minimum 24.27; maximum 36.82); amylin,
29.33 " 1.00 (minimum 24.27; maximum 36.82).
Fig. 5. Distribution of RAMP2 mRNA in relation to the other RAMPs. All
of the selected cells were CTRa+. (a) In vehicle Fos-GFP female rats
(n = 4/group), the collected AP single neurons (n = 9–10 cells/rat) were
mainly characterized as RAMP2+, being RAMP1+/RAMP2+/RAMP3+
(55%), RAMP1!/RAMP2+/RAMP3+ (13%), RAMP1+/RAMP2+/RAMP3!
(2%) and RAMP1+/RAMP2!/RAMP3+ (30%). (b) RAMP2 mRNA distribu-
tion in amylin-treated animals was as follows: RAMP1+/RAMP2+/RAMP3+
(53%), RAMP1!/RAMP2+/RAMP3+ (5%); RAMP1!/RAMP2!/RAMP3+
(12%) and RAMP1+/RAMP2!/RAMP3+ (30%).
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Our results also indicate that amylin has the potential to modify
individual components of its own receptors. The relative quantiﬁca-
tion of the mRNA levels revealed that the expression of RAMPs but
not of CTRa was differentially regulated by amylin. The mRNA of
the primary contributors necessary to form the functional AMY1,3
(RAMP1 and RAMP3) was consistently and signiﬁcantly down-
regulated by amylin, whereas CTRa mRNA seemed to be unaf-
fected. In contrast to RAMP1 and RAMP3, RAMP2 mRNA was
up-regulated after amylin administration. The functional conse-
quences of the latter effect are unknown at present. The RAMP2
transcript level could be elevated to allow the dimerization with the
calcitonin-like receptor in the rat AP, and therefore generate an adre-
nomedullin-responsive receptor over an AMY2. However, this was
not the purpose of our study.
The functional relevance of reduced RAMP1 and RAMP3
expression following amylin treatment is also currently unknown,
but could be related to changes in amylin sensitivity. Interestingly,
supporting evidence has shown that, when amylin was infused
chronically at high doses (i.e. 50 lg/kg/day), its inhibitory effect
on eating was stronger in the ﬁrst few days of infusion compared
with later time points (Lutz et al., 2001), suggesting a decrease in
amylin action. However, our recent work showed that, when rats
are chronically treated with more physiological doses of amylin
(5–10 lg/kg/day), the animals’ responsiveness to acute amylin
injections was maintained over time (Boyle et al., 2011). Based on
these data, we therefore hypothesize that amylin, especially when
administered at supraphysiological concentrations, acts on its own
primary receptors (AMY1,3) to modulate RAMP1 and RAMP3
mRNAs via a potential negative feedback regulation mechanism.
RAMP1 and RAMP3 may therefore act as the dynamic and regu-
latory component of the functional AMY1,3 in single AP neurons,
whereas CTRa may preferentially play a structural role as the core
AMY subunit.
A number of studies have shown that amylin increases leptin
sensitivity in leptin-resistant animals (Trevaskis et al., 2010). Lep-
tin exerts its eating and weight-lowering effects primarily by bind-
ing to LepRb. The LepRb-mediated effects on energy balance
seem to rely on a wide network of brain areas, including the ven-
tromedial nucleus and arcuate nucleus of the hypothalamus, but
possibly also regions in the brainstem, such as the nucleus of the
solitary tract, which is also rich in LepRb (Myers et al., 2009).
Although the ventromedial nucleus of the hypothalamus has been
proposed to mediate the interactions between leptin and amylin
(Trevaskis et al., 2010), the involvement of the caudal brainstem,
and speciﬁcally the AP, has not been fully examined. Interestingly,
LepRb has also been found within the AP, although in low abun-
dance (Wada et al., 2014). Moreover, chronic amylin treatment in
rats was shown to elevate both the basal and leptin-induced activa-
tion of phospho-signal transducer and activator of transcription 3
in the AP (Roth et al., 2008), thus supporting the idea that amylin
might also interact with leptin at the level of the AP (Trevaskis
et al., 2010). Here, we showed that, after acute amylin treatment,
30% of the single Fos-GFP+ AP cells co-expressed the transcripts
of LepRb and AMY. Moreover, amylin up-regulated AP LepRb
expression at the single-cell level. Our results therefore suggest the
presence of a ﬁrst-order neuronal population in the AP that is
responsive to both amylin and leptin. This idea is consistent with
recent ﬁndings that amylin and leptin are able to excite the same
neurons isolated from the rat AP, using a whole-cell current-clamp
recording technique (Smith et al., 2015). Further, our observation
that acute amylin treatment increased LepRb expression provides a
possible mechanism by which amylin enhances leptin sensitivity,
as was previously speculated (Trevaskis et al., 2010). The speciﬁc
contribution of AP neurons with LepRb to the effects of leptin on
eating and to the interaction between amylin and leptin will require
additional investigation.
The results from our current study provide the ﬁrst concrete evi-
dence that CTRa, RAMP1, RAMP2, RAMP3 and LepRb mRNAs
are all co-expressed in single amylin-activated neurons of the
native rat AP. Our data report transcriptional changes at the
mRNA level only. This limitation was mainly due to the lack of
availability of commercial antibodies against the RAMPs and
LepRb; further studies would be important to show that the AMY
components are also co-expressed at the protein level. Our data
support the possibility of there being more than one AMY subtype
in the same amylin-activated AP neuron. In addition, amylin has
the potential to self-regulate its own receptors by modifying the
transcriptional expression of the RAMPs. Finally, we showed that
LepRb mRNA is co-expressed along with CTRa and at least one
of the RAMPs in 30% of individual amylin-activated AP neurons.
These data indicate that the AP may directly contribute to the
interaction between amylin and leptin.
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6. Original Research article: “The satiating hormone amylin induces 
neurogenesis in the area postrema of adult rats”  
 
 
This section contains an original research article that was submitted for publication to 
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Abstract  
 
Adult neurogenesis in the subgranular zone and subventricular zone is generally 
accepted, but its existence in other brain areas is still controversial. Circumventricular 
organs, such as the area postrema (AP) have recently been described as potential 
neurogenic niches in the adult brain. The AP is the major site of action of the satiating 
hormone amylin. Amylin has also been shown to promote the formation of neuronal 
projections originating from the AP in neonatal rodents but the role of amylin in adult 
neurogenesis remains unknown. Here we performed an RNA-sequencing on the AP 
of adult rats and we showed that acute amylin affected genes involved in the control 
of adult neurogenesis (e.g; NeuroD1). Further, chronic amylin treatment (50 
µg/kg/day) increased the number of newly proliferated cells. Using different cell 
markers, these adult-born cells were characterized as neurons. These results support a 
novel role of amylin in promoting neurogenesis in the AP of adult rats. 
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Significance Statement  
Acute amylin treatment influences the transcription of many genes involved in 
neurogenesis-like processes (i.e; NeuroD1). Chronic administration of amylin 
strongly increases the number of newly proliferating BrdU-labeled cells in the AP of 
adult rats. The fate of the differentiated cells is mainly neuronal rather than glial. Our 
results show that amylin, next to its role as satiation signal, induces neurogenesis in 
the AP of adult rats. 
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Introduction  
 
It is widely accepted that that the generation of new neurons and glial cells occurs 
continuously in adult mammalian brains. The subgranular zone (SGZ) of the 
hippocampus (Eriksson et al., 1998; Kempermann and Gage, 2000) and the 
subventricular zone (SVZ) lining the lateral ventricle (Doetsch et al., 1999) are two 
well-known brain regions where neurogenesis occurs during adulthood. The exact 
molecular mechanisms underlying adult neurogenesis are not yet fully understood. 
New-born cells in the SGZ and SVZ migrate to the dentate gyrus (DG) to develop 
into mature neurons, and to the olfactory bulb to became interneurons, respectively. 
Growing evidence supports the role of Ephrin-signaling to modulate the synaptic 
structure and physiological properties of neurons throughout their lifespan (Murai and 
Pasquale, 2004). In the adult brain, Ephrin receptors (EphRs) are expressed in the 
synaptic terminals where they influence synaptic plasticity and the commitment to 
neuronal fate (Murai and Pasquale, 2004). Moreover, the neurotransmitter gamma-
amino-isobutyric acid (GABA) exerts similar actions in the adult brain by playing a 
key role in the control of multiple steps of adult neurogenesis.  GABAA-receptors are 
involved in synaptogenesis and plasticity in the adult brain and contribute to the 
proliferation, migration and differentiation of adult-born neurons (Fritschy and 
Panzanelli, 2014). Interestingly, in hippocampal slices, acute GABA application 
increased the expression of the transcription factor NeuroD (neuronal differentiation) 
within the SGZ (Tozuka et al., 2005). NeuroD is a positive regulator of neuronal 
differentiation in the terminal differentiation stage of the granule cells in the dentate 
gyrus (DG) (Tozuka et al., 2005). Finally, GABA-induced depolarization seems to be 
required for the integration of new neurons into the existing neuronal circuit, e.g. in 
the olfactory bulb (Belluzzi et al., 2003; Tozuka et al., 2005).  
!! 51!
The occurrence of neurogenesis and gliogenesis has also been demonstrated in 
circumventricular organs (CVOs), including the area postrema (AP) (Bennett et al., 
2009; Hourai and Miyata, 2013; Lin et al., 2015). The AP is a medullary structure 
located at the inferoposterior border of the fourth ventricle in the brainstem. The AP 
belongs to the family of sensory CVOs, which includes also the organum vasculosum 
of the lamina terminalis (OVLT) and the subfornical organ (SFO). CVOs are defined 
as “windows of the brain” because they possess permeable fenestrated capillaries and 
a highly deficient blood-brain-barrier (BBB) that allows neurons in the CVOs to 
directly receive information from the blood supply to control homeostatic functions 
(i.e., pH balance, blood pressure, temperature, energy balance via hormones and 
metabolites, etc.) (Gross and Weindl, 1987; Joly et al., 2007; Roth et al., 2004). The 
lack of tight junctions in the CVOs, and specifically in the AP, might also allow 
access to important physiological stimuli that could further regulate neurogenesis in 
the adult brain (Lin et al., 2015).  
The AP is a major brain site that mediates the effects of the satiating hormone amylin 
(Lutz, 2009; Lutz et al., 1998b; Riediger et al., 2001; Riediger et al., 2004). Amylin is 
co-secreted with insulin in response to nutrient stimuli (Lutz, 2010a) and mainly acts 
as a satiation signal to decrease food intake and body weight (Lutz et al., 1994; 
Trevaskis et al., 2010a). Amylin also inhibits glucagon secretion (Gedulin et al., 
1997) and delays gastric empting (Young et al., 1995) via the AP. Although amylin-
based research has primarily focused on its role in controlling food intake and body 
weight, a growing body of evidence suggests that amylin has additional effects on 
neuronal function. We previously showed that neonatal, amylin-deficient mice have 
reduced neuronal projections from the AP to the nucleus of the solitary tract (NTS), 
demonstrating that amylin has the potential to function as a trophic factor in the brain 
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(Lutz, 2010b), as had been shown earlier in the kidney, bone and pancreas (Lutz, 
2010b; Wookey et al., 2006). It has also been shown that amylin may exert a 
neuroprotective effect in the brain. Chronic treatment with the amylin analog 
pramlintide improved memory and cognition, and ameliorated hippocampal pathology 
in a mouse model of Alzheimer’s disease (Adler et al, 2014).  Moreover, reduced 
neurogenesis in the hippocampus and the AP observed after ovariectomy in adult 
female rats was rescued by chronic infusion of amylin (Trevaskis et al, 2010). 
However, how amylin exerts the aforementioned effects is still unknown.  
To investigate a possible role of amylin in enhancing neurogenesis in the AP of adult 
rats, we first used next generation sequencing (Ngs) to investigate the genes 
differentially affected by acute amylin treatment.  Second, we examined whether 
chronic amylin infusion increased cell proliferation and differentiation in the AP of 
adult rats, using the BrdU-labeling and double fluorescence immunohistochemistry 
techniques. 
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Results 
 
Acute amylin treatment affected pathways and Gene Ontology (GO) processes that 
participate in the regulation of neurogenesis.  
 
To investigate the transcriptome of the entire AP of adult rats, animals (n= 5 per 
group) were acutely treated with vehicle, amylin (20 µg/kg) or with amylin and the 
amylin antagonist AC187 (500 µg/kg). cDNA libraries were generated from the 
extracted RNA and sequenced. Ngs data were processed with enrichment analysis for 
biological pathways and GO processes. Pathways analysis revealed that Cell 
adhesion_Ephrin signaling, neurophysiological process_GABAA-receptor life cycle 
and neurophysiological process_ GABAB-receptor signaling at postsynaptic sides of 
the synapsis pathways were the top-three pathways which involved genes affected by 
acute amylin treatment (Table 1).  
GO analysis described a scenario in which most of the genes that were affected by 
amylin in the AP are involved in neurogenesis-like processes, in particular in synaptic 
transmission, nervous system development, cell-cell signaling and neurogenesis 
(Table 2).  A cross analysis between the major pathways and GO processes revealed 
the NeuroD (Neuronal-differentiation) gene family as the main group of genes 
involved in the aforementioned processes. Network analysis defined a major gene 
map in which members of the Ephrin-receptor signaling pathway, the GABAA-
receptor signaling pathway, and genes involved in the regulation of neurogenesis (i.e., 
NeuroD1, WNT) all constitute an effective gene network affected by acute amylin in 
the AP of adult rats (Figure 1).  
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Acute amylin administration significantly upregulated NeuroD1 transcript and 
protein in the AP of adult rats, and this response was completely blocked by the 
administration of AC187. 
NeuroD1 is a member of the NeuroD gene family which is required in the final step 
of the neural stem cell differentiation to acquire the neuronal cell fate (Gao et al., 
2009; Pataskar et al., 2015). Results from the GO enrichment analysis (Table 2) 
showed that the majority of the genes identified via the Ngs are involved in 
neurogenesis-like processes; further, the gene network (Figure 1) described a scenario 
in which NeuroD1 may interact, via canonical and unknown pathways, with EphRs 
and GABAA-receptors signaling to mediate amylin’s effect on neurogenesis-like 
processes. 
We further validated the effect of amylin on NeuroD1 mRNA expression by qPCR 
and found that acute amylin treatment significantly upregulated NeuroD1 transcript 
levels about 13 fold, and that this effect was completely reversed by AC187 (Figure 
2a; One-way ANOVA; F(2,12) = 18.96, ***P = 0.0002). We also confirmed the 
upregulation at the protein level and showed that rats (n=3 per group) that were 
acutely treated with amylin (20 µg/kg; i.p.) exhibited a marked upregulation of 
NeuroD1 (Figure 2b-d; Student t-test; t4=9.774, ***P= 0.0006 [Figure 2b]). The 
number of positive cells (i.e; number of particles) was quantified with Image J 
version 1.49b. 
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Chronic amylin treatment significantly increased the number of newly proliferating 
(BrdU-labeled) cells after one-week treatment in the AP of adult rats. 
 
To further investigate the role of amylin in adult neurogenesis, animals (n=8 per 
group) were chronically treated with amylin (50 µg/kg/d) or vehicle (Figure 3 a,b). 
Based on the premise that new cells are continuously generated in the AP of adult rats 
(Bennett et al., 2009; Hourai and Miyata, 2013), we examined the number of 
proliferating cells by analyzing BrdU-immunoreactive (BrdU-labeled) cells. After 
one-week of amylin infusion, the number of BrdU-labeled cells was significantly 
increased compared to controls (Student t-test; t12= 3.978, **P= 0.0018; Figure 3c). As 
a positive control for an effect of amylin, food intake was measured daily throughout 
the experiment; as expected (Lutz et al., 2001), amylin effectively decreased 24-hours 
food intake (but not body weight) compared to controls (Student t-test; t14= 2.574, *P 
< 0.05; Supplementary Figure 1a,b). 
 
 
BrdU-labeled cells mainly differentiated into neurons after three-weeks of chronic 
amylin treatment in the AP of adult rats.  
To determine the cell fate of the newly born cells in adult rats, we performed a series 
of immunohistological double-labeling stainings using different cellular markers after 
three weeks of amylin treatment (Figure 4). Immature and mature neurons were 
stained with the neuronal marker HuCD (Figure 4; b,e) and BrdU+/HuCD+ double-
labeled cells were mainly present in the central region of the AP (Figure 4f). Glial 
cells were identified with the glial marker GFAP (Figure 4h,k) and BrdU+/GFAP+ 
double-labeled cells were predominantly located at the borders of the AP (Figure 4i,l). 
The number of BrdU-labeled cells was higher in rats chronically treated with amylin 
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compared to controls (Student t-test; t15=2.163, *P=0.0471; Figure 5a). Moreover, 
amylin significantly increased the number of BrdU+/HuCD+ double-labeled cells, 
compared to control (Student t-test; t15=6.059, *P < 0.0001; Figure 5b). Finally amylin 
significantly raised the percentage of double-labeled cells in respect to the percentage 
of BrdU-positive cells (Student t-test; t15=5.563, *P < 0.0001; Figure 5c). Confocal 
quantification confirmed the double-staining observed under fluorescence microscope 
(Figure 6a) and showed that amylin preferentially induced neuronal rather than glial 
cell fate (One-way ANOVA; F(3,28)= 27.51; ****P < 0.0001; Figure 6b).  
To confirm a chronic amylin effect, food intake and body weigh were monitored daily 
during the experiment. 24-hours food intake (but not body weight) was significantly 
decreased by amylin during the three-week treatment period (Student t-test; t14=2.718, 
*P=0.0167; Supplementary Figure 1c,d).  
Finally, to exclude a possible co-localization of BrdU-labeled cells with interneurons 
or blood vessels, we performed immunohistochemical analysis for the interneuronal 
marker claretitinin (CR) (Supplementary Figure 2 a-f) and the blood-vessel marker 
RECA-1, respectively (Supplementary Figure 2 g-m). We did not detect any co-
localization of BrdU-labeled cells with CR (Supplementary Figure 2f), indicating that 
chronic amylin does not seem to promote the differentiation of newborn cells into 
interneurons in the AP. Abundant RECA-1 staining was found in the AP, confirming 
its highly vascularized structure (Supplementary Figure 2h,l); however, no co-
localization between BrdU and RECA-1 was detected in the AP of adult rats 
(Supplementary Figure 2i,m). 
 
 
!! 57!
Discussion 
 
We demonstrate that acute amylin treatment affected the regulation of genes that are 
involved in neurogenesis-like processes. In particular, the Ngs data analysis showed 
that acute amylin treatment consistently affected Ephrin-signaling and GABAA-
signaling pathways. Moreover, GO processes revealed that acute amylin affected 
genes mainly involved in synaptic transmission, nervous system development, cell-
cell signaling and generation of new neurons. NeuroD1 was identified as the major 
gene up-regulated by acute amylin administration. This effect was reversed by the 
administration of the amylin receptor antagonist AC187, and immunohistochemistry 
confirmed the increase in NeuroD1 expression by amylin also at the protein level. 
These findings are consistent with previous evidence of the involvement of EphR 
signaling, GABAA-receptors signaling and NeuroD-gene family signaling, in the 
regulation of different steps during adult neurogenesis (Fritschy and Panzanelli, 2014; 
Murai and Pasquale, 2004; Tozuka et al., 2005). 
Moreover, our BrdU study confirmed previous findings that CVOs, including the AP 
of adult rats, contain constitutively proliferating cells that go on to differentiate into 
neurons and glia (Bennett et al., 2009; Lee et al., 2012). Therefore, CVOs might be 
considered as new neurogenic niches (Lin et al., 2015), next to their role in mediating 
homeostatic controls in the adult brain. In vivo, we observed a clear effect of chronic 
amylin treatment on the AP of adult rats and we report that amylin not only increased 
cell proliferation, but also promoted the commitment to neuronal fate of adult-born 
AP-cells. In fact, confocal microscopy analysis demonstrated that the majority of 
newly proliferated cells in the AP of adult rats differentiated into neurons. Only a 
small percentage of adult-born cells, mainly located at the edges of the AP, 
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differentiated into glia three weeks after BrdU labeling.  
At present, the functional significance of continuous neurogenesis in the adult AP is 
not well understood. A potential explanation could be that the generation of new 
neurons is required to control homeostasis. Specifically, the ongoing neurogenesis 
might be responsible for a fine control of food intake and vomiting (Lutz, 2006; 
Miller and Leslie, 1994), two main actions controlled by the AP by a large number of 
physiological or pathological stimuli. Hence, the necessity for the constitutive 
neurogenesis in the adult AP might resides in the “CVO-nature” of the AP. The lack 
of a BBB, and the possible negative influence on AP neurons due to blood-derived 
substances might affect the efficiency and survival of the AP-neurons. Therefore, the 
presence of new neurons in this brain area might suggest a protective mechanism of 
neuronal repair. Interestingly, other brain areas involved in nutrient sensing and in the 
control of eating have also been reported to shown adult neurogenesis.  In the median 
eminence, tanycytes from the ependymal zone generate new neurons that contribute 
to the control of food intake (Lee et al., 2012). In the arcuate nucleus, the ciliary 
neurotrophic factor mediates continuous neurogenesis which has been shown to affect 
the long-term regulation of energy balance (Kokoeva et al., 2005).  
Recent work from our group showed that neonatal, amylin-deficient mice have 
reduced neuronal projections from the AP to the NTS, demonstrating that amylin has 
the potential to function as a trophic factor in the brain of newborn rats (Lutz, 2010b).  
Moreover, chronic amylin administration was shown to compensate for the reduction 
in neurogenesis in the hippocampus and AP observed in adult female ovariectomized 
rats (Trevaskis et al, 2010).  Finally, it was also shown that chronic treatment with 
pramlintide, an amylin analogue, improved memory and cognition and ameliorated 
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hippocampal pathology in a mouse model of Alzheimer’s disease (Adler et al, 2014). 
These findings suggest that amylin-induced neurogenesis in adult rats may play a 
previously unappreciated role in physiology and disease. How amylin exerts the 
aforementioned effects is unknown at present. A potential mechanism might involve 
amylin-signaling via the extracellular signal-regulated kinase 1 and 2 (ERK 1/2) 
cascade. It has been shown that ERK1/2 knockout mice have impaired neurogenesis, 
suggesting that ERK1/2 activity is required for the generation of new neurons (Satoh 
et al., 2011). Further, our own studies showed that amylin time and dose-dependently 
activates ERK 1/2 signaling, by inducing ERK phosphorylation. Since pERK-positive 
AP-neurons partially overlap with the core subunit of the amylin receptor, calcitonin-
receptor (CTR) (Potes et al., 2012), this effect seems to be mediated by CTR-
signaling. These findings suggest that amylin may influence AP-adult neurogenesis 
via ERK phosphorylation. 
It also remains to be addressed how the adult-born AP-neurons are functionally 
integrated into pre-existing circuits and how amylin influences this process. Future 
work is needed to determine whether amylin also enhances neurogenesis in the AP of 
newborn rats.   
 
To confirm the presence of an amylin effect, food intake and body weight were 
monitored daily throughout the course of the chronic experiment. Food intake was 
significantly reduced in amylin-treated rat compared to control. Unexpectedly, amylin 
did not exert a lasting effect on body weight. As weight loss per se is known to induce 
neurogenesis in the hippocampus (Mattson, 2000), we can therefore exclude an effect 
of decreased body weight as a source of increased neurogenesis in the AP of adult 
rats.  
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In summary, our results indicate that amylin increases the production of new neurons 
in the AP of adult rats. Analyses of biological pathways, GO processes and gene 
network suggest that acute amylin differentially regulates genes involved in 
neurogenesis-like processes in vivo. A potential mechanism for this phenomenon may 
relate to an activation of a complex cellular network by amylin, possibly involving 
ERK1/2 signaling and operating via EphRs and GABAA-receptor pathways. This 
might lead to the activation of NeuroD1, which acts as the necessary signal to commit 
adult-born AP-cell to the neuronal fate. Moreover, chronic amylin treatment increased 
both cell proliferation and cell differentiation into neurons. These results support a 
novel role of amylin in the processes of adult AP neurogenesis, providing new 
insights into the mechanism of neurogenic regulation.  
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Materials and methods 
 
Animals and housing 
Adult male Wistar rats (Janvier, Le Genest Saint Isle, France) (220-250 g) were used 
for the experiments and were single-housed in a temperature-controlled environment 
(21±1°C) on an artificial 12h/12h light/dark cycle. Rats had ad libitum access to water 
and standard chow, except during fasting periods as described below. All procedures 
involving animals and their care were approved by the Veterinary Office of the 
Canton Zurich, Switzerland, and in accordance with the EU Directive 2010/63/EU on 
the protection of animals used for scientific purposes. 
 
Drugs 
Amylin (Bachem AG, Bubendorf, Switzerland; catalogue number: H-9475.1000) was 
reconstituted with sterile 0.9% NaCl and AC187 (TOCRIS Bioscience, Bristol, UK; 
catalogue number: 3419) was reconstituted in sterile double-distillated water. 5’-
bromo-2-deoxyuridine (BrdU, B5002, Sigma Aldrich, Buchs, Switzerland) was 
dissolved in sterile double-distillated water and heated to 40-50°C.  
 
Experimental design 
 
Experiment 1 
For the Ngs experiment, rats (220-250 g; n=5 per group) were fasted during the light 
phase. At dark onset, rats were acutely treated i.p. with vehicle (NaCl), amylin (20 
µg/kg), or with amylin plus the amylin receptor antagonist, AC187 (500 µg/kg). 
Ninety minutes after drug administration, rats were anesthetized with isoflurane and 
decapitated; during this 90-min period, rats had no access to food. 
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RNA extraction  
After decapitation, the AP was surgically removed from the hindbrain under a light 
microscope and RNA was extracted according to manufacturer’s instructions (TRI 
Reagent®; Sigma-Aldrich, Buchs, Switzerland) and then purified following the 
cleanup protocol of RNeasy® Mini kit (Qiagen, Basel, Switzerland), including the 
DNase step. The concentration and the integrity of RNA were measured using a 
nanodrop system (NanoDrop 1000 Spectrophotometer, (Thermo Scientific, Waltham, 
MA, USA).  
 
Strand-specific cDNA library construction  
From each sample, 10 ng of total RNA were taken to construct strand-specific cDNA 
libraries using the Ovation® Single Cell RNA-Seq System (PART NO. 0342, 
NuGEN; San Carlos, California). The quality of cDNA libraries was tested and 
quantified cDNA was subjected to purification, elution, end-repair and adaptor 
ligation. A second round of library amplification and purification was performed, 
following the manufacturer’s instruction. Samples were screened by bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA) and qPCR. The established cDNA 
libraries were sequenced using the Illumina HiSeq 2000 platform (Ilumina Inc., San 
Diego, CA, USA) to generate 100bp paired-end reads. 
 
Quantitative real-time PCR (qPCR)  
Total RNA was reverse transcribed with Tetro cDNA Synthesis Kit (Bioline, Elchrom 
Scientific AG, Cham, Switzerland). Real-time PCR was performed using 7500 Fast 
system (Applied Biosystem/Life Technologies Carlsbad, CA, USA) with 
QuantiTect® SYBR® green PCR kit (Qiagen, Basel, Switzerland). Intron-spanning 
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primers were designed with IDT, Integrated DNA Technologies, 
(http://eu.idtdna.com). The primer sequences were the following: for rat GAPDH, 
forward: 5’-AGACAGCCGCATCTTCTTGT-3’ and reverse: 5’-
CTTGCCGTGCGTAGAGTCAT -3’ (Accession: NM_017008.4); for rat NeuroD1, 
forward: 5'-GAACACGAGGCAGACAAGAA-3' and reverse: 5'-
TCATCTTCATCCTCCTCCTCTC-3' (Accession: NM_019218.2). 100 ng of cDNA 
were subjected to an initial heat activation at 95 °C for 15 minutes, followed by 40 
cycles of alternating between 94 °C for 15 sec, 60 °C for 30 sec, and final extension at 
72°C for 30 sec. The fold change in expression of each gene was calculated using the 
comparative ΔΔCt method, with GAPDH as endogenous control. Each sample was 
run in duplicate. !
Enrichment analysis for pathways, GO processes and gene network construction  
The list of ranked genes for each sequencing batch and the list of susceptibility genes 
were imported into MetaCore™ software version 6.24 (Thomson Reuters, New York, 
NY, USA). Enrichment analysis for pathways and GO processes was performed on 
gene expression data to identify significant pathways and processes affected by our 
experimental conditions. Enrichment analysis comprised both up- and down- signals, 
distribution was achieved by intersection setting and the sorting method was based on 
statistically significant data (threshold=2 and p-value ≤ 0.01). Analysis was 
performed via the online platform portal.genego.com version 6.20.66481. To 
determine the pathways associated with the susceptibility genes, a sub-enrichment 
analysis was performed on the list of these genes. Pathways are represented by the 
GO set class of biological processes. Finally, to determine the interactions between 
susceptibility genes from the different functional groups, gene networks were 
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constructed. Data files were analyzed with MetaCore+MetaDrug® version 6.19 build 
65960 scripts 65979. 
Tissue preparation 
Animals were deeply anesthetized with an i.p. injection of sodium pentobarbital (100 
mg/kg) and transcardially perfused using 0.1M PBS followed by 4% 
paraformaldehyde (PFA).The brains were collected and maintained overnight in 4% 
PFA. Subsequently, the brains were transferred to 20% sucrose in PBS for 24 hours. 
Brains were cut into 20-µm coronal sections on a cryostat (Leica microsystem, 
Wetzlar, Germany) and stored in cryoprotectant (20% glycerol, 30% ethylene glycol, 
50% 0.1M PB) until processing for immunohistochemistry. 
 
Immunohistochemistry 
Slide-mounted sections (20 µm) were washed in 0.1M PBS (pH 7.4) and then 
incubated in immunoblocking buffer  (2.5% bovine serum albumin [BSA], 0.1% 
Triton X-100 in PBS) for 1 h at room temperature. Subsequently, sections were 
incubated with Rabbit anti-NeuroD1 primary antibody (1:250, Abcam, Cambridge, 
UK). After overnight incubation at 4°C, the sections were washed in PBS and 
incubated for 3 h with fluorescent secondary antibody Alexa Fluor 488 Donkey anti-
rabbit immunoglobulin G (IgG) (1:400, Invitrogen, MOLECULAR PROBES®, 
Eugene, Oregon, USA). The nuclear dye DAPI (4',6-diamidino-2-phenylindole; 
Sigma-Aldrich, Buchs, Switzerland) was added to secondary antibodies solution for 
nuclear staining. Sections were then rinsed in PBS and coverslipped with fluorescent 
mounting medium. 
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Experiment 2 
Rats (220-250 g; 4 groups and n=8 per group) were acclimatized in their home-cage 
environment. Amylin (50 µg/kg/d) or vehicle was chronically administered 
peripherally by subcutaneous osmotic minipumps (Alzet®, Model 2002; Durect 
Corporation; Cupertino, CA, USA) for seven days or three weeks, respectively. On 
the day of implantation, the minipumps were filled under sterile conditions with saline 
or amylin. Rats were initially anesthetized by inhalation of 5% isoflurane (IsoFlo®, 
Provet AG, Lyssach, Switzerland), then maintained on 2-3% isoflurane and placed on 
a heating pad to maintain body temperature during surgery. At the site of 
implantation, rats were shaved and the skin was disinfected with Betadine® (Provet 
AG, Lyssach, Switzerland). Under sterile conditions, a small incision was made 
between the scapulae and the minipump was subcutaneously implanted. The wound 
was closed with interrupted cutaneous sutures. Food intake and body weight were 
measured daily. 
BrdU injection 
BrdU was used to label proliferating cells and to track the fate of newly proliferated 
cells. Rats were given twice daily intra-peritoneal (i.p) injections of BrdU (75 µg/kg; 
12 h apart) for 6 days, starting on the day of amylin treatment. To determine the rate 
of newborn cells, part of the rats were sacrificed on day 7, i.e. 12h after the last BrdU 
injection; the remaining rats were allowed to survive for an additional two weeks and 
then sacrificed at the end of the 3-week amylin infusion period, to investigate the fate 
of the BrdU-labeled cells. 
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Tissue preparation 
Animals were treated following the protocol described in Experiment 1, with two 
exceptions: here, tissues were stored in a solution of 30% sucrose in PBS for 48 hours 
and brains were cut into 30-µm coronal sections.  
 
Double fluorescence Immunohistochemistry  
Free-floating sections were pretreated to denature the DNA to make the BrdU 
antibody detectable. Briefly, AP sections were incubated in a solution of 50% 
formamide for 2h at 65°C; then, sections were incubated in 2N HCl for 30 min at 
30°C and subsequently acid neutralized with 0.1 M borate buffer for 10 min. After 
washing in 0.1M PBS (pH 7.4), sections were incubated in immunoblocking buffer 
(3% goat serum [NGS], 1% bovine serum albumin [BSA], 0.3% Triton X-100 in 
PBS) for 1 h. Primary antibodies were applied as a cocktail that included rat anti-
BrdU primary antibody (1:100, Abcam, Cambridge, UK), mouse anti-HuC/D (1:100, 
Thermo Fisher Scientific, Wahltman, MA, USA), rabbit anti-DCX (1:1000, Abcam, 
Cambridge, UK), rabbit anti-GFAP (1:1000, Abcam, Cambridge, UK), mouse anti-
RECA-1 (1:2000; AbD Serotec, Kidlington, UK) or rabbit anti-calretinin (CR) (1:100, 
Abcam, Cambridge, UK). After overnight incubation at 4°C, the sections were 
washed in PBS and incubated for 4 h with fluorescent secondary antibodies, also 
applied as a cocktail: Alexa Fluor 488 goat anti-rat immunoglobulin G (IgG) to reveal 
immunoreactivity of BrdU and Alexa Fluor 555 goat anti-rabbit to reveal 
immunoreactivity of GFAP, RECA, DCX and CR IgG, respectively (1:400 for all the 
antibodies; Invitrogen, MOLECULAR PROBES®, Eugene, Oregon, USA), or Alexa 
555 goat anti-mouse to reveal immunoreactivity of HuCD. Then, the sections were 
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rinsed in PBS and mounted onto Superfrost glass slides (Thermo Scientific, Waltham, 
MA USA) and coverslipped with fluorescent mounting medium. 
 
Cell quantification and Analysis 
Two AP sections per brain were counted and averaged to determine the number of 
BrdU-labeled cells. Counting was accomplished at 20 X magnification and numerical 
aperture of 0.5, using a light microscope (Zeiss Imager Z2; Carl Zeiss, Jena, 
Germany) equipped with a color camera (Zeiss Axiocam; Carl Zeiss, Jena, Germany). 
For cell differentiation experiments, fluorescent double-labeled sections with 
BrdU+/HuCD+ cells and BrdU+/GFAP+ cells were visualized and analyzed on CLSM 
Leica TCS SP8 upright confocal microscope (Leica Microsystem, Wetzlar ,Germany) 
equipped with an x-y-z motorized stage and three lasers (Argon 488, HeNe 543 and 
HeNe 633) appropriate to detect DAPI, Alexa 555 and Alexa 488 fluorescence, 
respectively. Each laser channel was separately scanned using a multitrack PMT 
configuration to avoid cross-talk between fluorescent labels. A careful examination of 
all secondary antibodies was performed to avoid any possible cross-talk between 
fluorescent dyes or any cross-reactivity between secondary antibodies. To evaluate 
double-labeling, confocal z-stack sectioning was performed at 0.5-1.0-µm intervals 
using 40 X oil-immersion (NA= 1.30) or 63 X oil-immersion (NA=1.40) objectives. 
Images were acquired and 3D-reconstructed using the Zeiss LSM software, cropped 
and optimized in Imaris Software version 6.4.0 (Bitplane AG, Zurich, Switzerland). 
Colocalization of BrdU with HuCD or GFAP, respectively, was confirmed by 
examining multiple optical planes for each cell on the z-axis. The percentage of 
BrdU-positive cells double-labeled for HuCD or GFAP was determined by eye 
counting. The experimenter was blinded to the treatment (amylin versus control). 
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Supplemental material 
Suppl. Figure 1 shows 24 hours-food intake and body weight of rats after one and 
three-weeks of amylin treatment, respectively. Suppl. Figure 2 shows lack of co-
localization of BrdU with the interneuron marker CR and of BrdU and the blood 
vessel marker RECA-1. 
 
Statistical analysis 
Relative mRNA expression levels were assessed by one-way ANOVA. BrdU-labeled 
cells and food intake were quantified and then compared using Student’s t-test or one-
way-ANOVA, as appropriate, by using GraphPad Software version 6.0 (San Diego, 
CA, USA). 
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Abbreviation list 
 
AP, area postrema; BrdU, 5’-bromo-2-deoxyuridine; BBB, blood-brain barrier; CNS, 
central nervous system; CVO, circumventricular organ; CR, Calretinin; CTR; 
calcitonin receptor; DG, dentate gyrus: EphRs, Ephrin receptors; ME, median 
eminence; GABA-A Receptor, Gamma-Aminobutyric Acid A Receptor); GFAP, glial 
fibrillary acidic protein; GO, gene onthology; NeuroD; neuronal differentiation; 
NeuroD1, neuronal differentiation-1; Ngs, next-generation-sequencing; NTS, nucleus 
tractus solitarius; OVLT, organum vasculosum of the lamina terminalis; SFO, 
subfornical organ: SGZ, subgranular zone: SVZ, subventricular zone. 
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Figures and Figure legend 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
Top gene network in response to acute amylin. Network analysis (generated with 
MetaCore+MetaDrug®) of the genes whose expression was affected by amylin 
treatment are shown. Major functions of the network are indicated. See the legend for 
details. 
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Figure 2 
NeuroD1 mRNA and protein expression was significantly increased by acute amylin 
treatment. (a) qPCR analysis showing NeuroD1 mRNA expression levels in vehicle, 
amylin (20 µg/kg) and amylin+AC187 (500 µg/kg) treatments (n=5 rats per group). 
Amylin consistently and significantly up-regulated NeuroD1 mRNA expression 
compared to vehicle. AC187 reversed the amylin effect (One-way ANOVA, 
***P=0.002). mRNA levels are shown as fold change and GAPDH is used as internal 
control. Data are expressed as mean ± S.E.M. (b) Quantification of NeuroD1 protein. 
(c) Immunohistochemistry of NeuroD1 in AP sections of a vehicle (c) and amylin (d) 
treated rat, respectively. The inset shows co-localization of NeuroD1 and DAPI. Scale 
bar represents 50 µm. 
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Figure 3 
Amylin (50 µg/kg) increased the number of BrdU-positive cells after one week of 
treatment. (a) Immunohistochemical staining of BrdU-positive cells in AP sections of 
vehicle (a) and amylin (b) treated rats, respectively (n=8 rats per group). (c) Amylin 
significantly increased the number of BrdU-immunoreactive cells compared to control 
(Student t-test; **P = 0.0018). Data are expressed as mean ± S.E.M. Scale bar 
represents 50 µm. 
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Figure 4 
BrdU-labeled cells in the AP of vehicle (a,g) and amylin (d,j) treated rats (n = 8 per 
group); amylin was given for 3 weeks at a dose of 50 µg/kg/day. Sections stained for 
neuronal (HuCD) and glia (GFAP) markers, respectively, are shown in (b,e,h,k). 
Newly generated BrdU-positive neurons double labelled for HuCD and GFAP are 
shown in (c,f) and (i,l), respectively. The insets show examples of colocalization of 
BrdU and HuCD (f), which represent neurons, or colocalization of BrdU and GFAP 
(l), which represent glial cells. Scale bar represents 50 µm. 
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Figure 5 
Quantitative analysis of BrdU+ and double-labeled AP cells after 3 weeks of vehicle 
or amylin (50 µg/kg) treatment (n=8 rats per group). (a) Amylin significantly 
increased the number of BrdU-labeled cells after 3 weeks of treatment (t-test; *P < 
0.05). (b) The number of double labelled cells (BrdU+/HuCD+) cells was increased 
after amylin treatment, compared to control (t-test; ****P < 0.001). (c) The percentage 
of double-labelled BrdU+/HuCD+ cells in respect to the total number of BrdU+ cells 
(t-test; ****P < 0.001). Data are expressed as mean ± S.E.M.  
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Figure 6 
Quantification of double-labeled cells. (a) Confocal z-stack image showing the co-
localization of BrdU+ and HuCD+ cells. Scale bar represents 5 µm. (b) Number of 
double-labeled BrdU+/GFAP+ and BrdU+/HuCD+ cells in the AP of adult rats. Adult-
born cells preferentially committed to neuronal rather than glial fate after chronic 
amylin (50 µg/kg/d) treatment (One-way ANOVA, b= ****P<0.0001). Data are 
expressed as mean ± S.E.M.  
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Supplementary Figure 1 
Amylin’s effect on food intake and body weight in animal sacrificed after one or three 
weeks.  Average daily cumulative food intake over the 1-week (a) and 3-weeks (c) 
treatment period was significantly decreased by amylin (Student t-test; *P < 0.05). No 
difference in body weight was observed throughout the course of the experiment was 
observed (b, d). Data is expressed as mean ± S.E.M.  
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Supplementary Figure 2 
BrdU-labeled cells in the AP of vehicle (a,g) and amylin (d,j) treated rats (n = 8 per 
group); amylin was given for 3 weeks at a dose of 50 µg/kg/day. Sections stained for 
interneurons (CR) and blood-vessels (RECA-1) markers, respectively, are shown in 
(b,e,h,l). BrdU-positive neurons double labelled for CR (c, f) and RECA-1 are shown 
in (c,f) and (i,m), respectively. No co-localization was observed. Scale bar represents 
50 µm. 
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7. Unpublished results 
 
In this section I will briefly summarize preliminary data collected with the double 
transgenic Nestin/hRAMP1 mice. The aim of this pilot study was to provide a basic 
characterization of the feeding behavior of the double transgenic mice maintained on 
regular chow and on HFD. Further, to investigate the potential role of RAMP1 to 
enhance amylin and/or leptin central signaling, we performed crossover studies on 
two cohorts of animals and evaluated the meal pattern after each treatment. The brains 
of the Nestin/hRAMP1 and control mice (i.e., single-transgenic mice containing only 
the hRAMP1 or Nestin transgene) have been accurately preserved for future 
immunohistochemical analysis. Similarly, the carcasses of the animals have been 
stored for further CT-scan. The expected outcomes and the potential implications for 
our findings are discussed in ¶ 7.6.1.  
 
 
7.1 Characterization of the feeding behaviour of the Nestin/hRAMP1 double 
transgenic mice maintained on chow and high-fat diet. 
 
7.2 Background 
hRAMP1 is a 148 aa protein with a large extracellular domain, a single predicted 
transmembrane spanning domain and a short cytoplasmic domain (Mallee et al., 
2002). The co-expression of RAMP1 with CTRa in the same single neuron, e.g. in the 
rat AP (Liberini et al., 2016), generates the AMY1, whereas the coupling of RAMP1 
with CLR generates CGRP receptors (McLatchie et al., 1998). The double transgenic 
mouse model Nestin-hRAMP1 expresses the human RAMP1 transgene in the brain, 
trigeminal ganglion, spinal cord and dorsal root ganglion (Zhang et al., 2011). 
Previous findings have shown that Nestin/hRAMP1 mice have reduced body weight, 
reduced adiposity and increased energy expenditure (Zhang et al., 2011). Thus, these 
double transgenic mice are characterized by a marked lean phenotype. It has been 
shown that both amylin and CGRP peptides reduce food intake and body weight 
(Lutz, 2006; Lutz et al., 1998a; Morley et al., 1996). Indeed, after 
intracerebroventricular (ICV) administration, amylin and CGRP decreased body 
weight and food intake in control animals, while Nestin/hRAMP1 mice showed an 
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enhanced response to amylin but not to CGRP. However, CGRP mRNA was elevated 
in the hypothalamus of the double transgenic mice (Zhang et al., 2011). These 
findings suggest that RAMP1 might enhance the central signaling of peptides 
involved in the regulation of feeding behaviour, such as amylin and CGRP. Moreover, 
RAMP1 might protect against obesity. Therefore, Nestin/hRAMP1 mice are an 
important tool to elucidate brain signaling in the context of the pathophysiology and 
intervention on obesity.  
 
Finally, the ability of RAMPs to modulate numerous aspects of G-protein-coupled 
receptor (GPCR) signaling makes them interesting pharmacological targets that may 
be useful for the development of specific drugs in humans and animals. GPCRs are 
located at the cell surface, which makes them easily accessible therapeutic 
(“drugable”) targets. Furthermore, they play a fundamental role in many cell types as 
the sensors or transmitter of extracellular chemical signals into messages resulting in 
cellular change. Indeed, GPCRs are, to date, among the most common types of 
pharmacologically-targeted molecules (Nickols and Conn, 2014; Roux and Cottrell, 
2014).   
 
 
 
7.2.1 Generation of the double transgenic Nestin/hRAMP1 mice 
 
Nestin/hRAMP1 mice are a double transgenic mouse model that results from the 
breeding of the transgenic mice Nestin/cre with the transgenic mice GFP/hRAMP1. 
Briefly, the cre gene is under the control of the nervous system specific promoter and 
enhancer rat nestin gene. The cre-mediated recombination system is a powerful and 
broadly utilized genetic approach to conditionally express (or delete) selected genes. 
Genotyping by PCR is required to identify the presence of the nestin gene and thus 
characterize a mouse as transgenic. GFP/hRAMP1 mice were previously generated by 
using a vector which contains the ubiquitous active Chicken-X1 (CX1) promoter 
upstream, and a downstream GFP-stop-hRAMP1 cassette flanked by loxP sites 
(Zhang et al., 2007b). The presence of GFP allows a rapid genotyping. By using Dark 
Reader device (Seville, 2001), GFP/hRAMP1 mice can easily be identified thanks to 
the green fluorescence visible on the nose, inner ears and paws. Once the mice have 
been correctly genotyped, male Nestin/cre are bred with female GFP/hRAMP1 mice 
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to express the human RAMP1 transgene. The GFP cDNA has a translational stop 
sequence and a polyA signal that prevents expression of hRAMP1 in these mice. 
Because of that, hRAMP1 expression is dependent on cre-recombinase excision of 
GFP at flanking loxP sites (Figure 7). The resultant hRAMP1 transgene is then 
expressed from CX1 promoter only in the nervous system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Breeding strategy for the generation of double transgenic Nestin/hRAMP1 mice.  
 
 
Nestin/cre male mice are characterized by the presence of the rat Nestin promoter and enhancer driving 
cre recombination. Male Nestin/cre mice are mated with female GFP/hRAMP1 mice to obtain 
Nestin/hRAMP1 progeny. GFP/hRAMP1 has a CX1 promoter and a GFP-stop-hRAMP1 cassette 
flanked by loxP sites. CX1 drives ubiquitous expression of GFP, but not hRAMP1, because the GFP 
cDNA has a translation stop codon and a polyadenylation signal (polyA). Cre mediates the excision of 
the GFP–stop sequence at the flanking loxP sites and the resultant progeny (Nestin/hRAMP1) have the 
hRAMP1 transgene expressed from the CX1 promoter only in the nervous system. Adapted from 
(Zhang et al., 2007a). 
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7.3 Aim 
 
To further characterize the feeding behaviour of Nestin/hRAMP1 transgenic mice, we 
performed meal pattern analysis using the BioDaq system which measures food 
intake, number of meals and meals size. Additionally, to evaluate a potential role of 
central RAMP1 in the interaction of amylin and leptin signaling (Roth et al., 2008; 
Trevaskis et al., 2010a), crossover studies were performed. Finally, to investigate 
whether an increased RAMP1 signaling might protect against obesity, we challenged 
the mice with high-fat diet (HFD; 60% fat with 0.25% added cholesterol; Research 
Diet, New Brunswick, NJ, USA). Meal pattern analysis was performed and energy 
expenditure was measured using an indirect calorimetry system. 
 
 
7.4 Design  
 
Experiment 1: Nestin/hRAMP1 mice (8-12 weeks old, n=7-8 per group) were 
acclimated for a week to the BioDaq Monitoring System before any data was 
collected. Animals had ad libitum access to water and standard chow (no. 3430; 
Provimi Kilba, Gossau, Switzerland) unless otherwise stated.  To acquire baseline 
measurements on chow, data were recorded for six days and the animals were 
manually weighted daily. Crossover experiments (vehicle versus amylin [50 µg/kg, 
i.p], vehicle versus leptin [5 mg/kg, i.p ] and vehicle versus amylin plus leptin, i.p) 
were carried on to the same cohort of animals with a three-day interval between 
trials. Prior to treatments, animals were fasted for two hours in the light phase and 
injected at dark onset. Feeding behavior parameters, such as food intake, number of 
meals and meal size were analyzed at 1, 2, 4, 12 and 24 hour post injections. Here, 
data are shown at 4 and 24 hours time points (Figure 8a). 
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Figure 8: Experimental plan 
 
Experiment 1: double transgenic Nestin/hRAMP1 mice and control (n= 6-7 per group) from the same 
cohort were initially adapted for a week to the BioDaq cage system. Mice were maintained on normal 
chow. After a week of baseline measurement crossover experiments with amylin (50 µg/kg), leptin (5 
mg/kg) and amylin plus leptin were performed. In Experiment 2, animals were adapted for two weeks 
to HFD. After a week of baseline measurement crossover experiments with amylin, leptin and amylin 
plus leptin were performed. Animals were finally treated with vehicle or amylin and sacrificed. 
 
 
Experiment 2: the same cohort of animals from Experiment 1 was then adapted for 
two weeks to HFD. To acquire baseline measurements on HFD, data were recorded 
for a week and animals were manually weighted daily. Crossover studies (vehicle 
versus amylin [50 µg/kg, i.p], vehicle versus leptin [5 mg/kg, i.p ] and vehicle versus 
amylin and leptin, i.p) were performed as described in Experiment 1. At the end of 
the experiment, mice were acutely treated with vehicle or amylin (50 µg/kg, i.p) 
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(Figure 8b). Forty-five minutes after injections animals were deeply anesthetized 
with an i.p. injection of sodium pentobarbital (100 mg/kg) and transcardially 
perfused using 0.1M PBS followed by 4% paraformaldehyde (PFA).The brains were 
collected and maintained overnight in 4% PFA. Subsequently, the brains were 
transferred to 20% sucrose in PBS for 24 hours. Brains were cut into 20-µm coronal 
sections on a cryostat (Leica microsystem, Wetzlar, Germany) and stored in 
cryoprotectant (20% glycerol, 30% ethylene glycol, 50% 0.1M PB) until processing 
for immunohistochemistry. The carcasses of the animals were stored at -20°C for 
further CT-scan analysis. Data were analysed by two-way ANOVA followed by 
Bonferroni post-hoc test to find differences between groups. Data are represented as 
mean ± S.E.M and statistical significance was established at P < 0.05. 
 
 
Experiment 3: for the metabolic study, Nestin/hRAMP1 mice (9-14 weeks old, n=6 
per group) were single housed in metabolic cages (TSE Phenomaster, TSE Systems, 
Germany) and adapted to the housing conditions for six days before starting the 
experiment. Animals had ad libitum accesses to water and HFD unless otherwise 
stated. Body weight and food intake were manually measured daily. A crossover 
study was performed: vehicle versus amylin (50 µg/kg, i.p) was administered to the 
mice at two-day intervals. Three days later, the same cohort of animals was treated 
with leptin (5 mg/kg, i.p) and sacrificed as described in Experiment 2. Brains and 
carcasses of the mice were stored at -20°C for further immunohistchemical and CT-
scan analysis. The respiratory exchange ratio (RER) and energy expenditure (EE) 
were calculated from O2 consumption and CO2 production as described previously 
(Riediger et al., 2010). EE data were normalized for body weight. The calculation was 
based on the following equation: total EE (kcal/kg/h) = (3.9 x VO2 + 1.1 x VCO2) / 
1000; RER = VCO2 / VO2. The day just before the injections was used as baseline and 
compared to the values obtained during the treatment period. Group means were 
analyzed with Student t-test. Data are represented as mean ± S.E.M and P < 0.05 was 
considered significant. 
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7.5 Results 
 
7.5.1 Nestin/hRAMP1 mice maintained on chow have reduced body weight, 
decreased food intake and a reduced number of meals per day. 
To investigate the role of the expression of neuronal hRAMP1, body weight, food 
intake, the number of meals per day and the meal size were monitored daily via the 
BioDaq system in Nestin/hRAMP1 double transgenic and control mice. 
Nestin/hRAMP1 mice showed a marked reduction in body weight (*P < 0.05) over 
time and decreased food intake (Student t-test; t13=2.350; *P = 0.0352) compared to 
controls (Figure 9 a,b). Detailed analysis of feeding behavior revealed that the number 
of meals per day was significantly lower in Nestin/hRAMP1 mice (Student t-test; 
t13=2.582; *P = 0.0228; Figure 9c) compared to control, whereas the meal size (grams 
ate/meal/mouse) was increased (Student t-test; t13=2.276; *P = 0.0404; Figure 9d). 
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Figure 9: Feeding behavior of Nestin/hRAMP1 mice maintained on chow. 
(
Baseline measurements of body weight, food intake and meal pattern analysis of Nestin/hRAMP1 mice 
maintained on chow. (a) Body weight was significantly lower in double transgenic mice, compared to 
controls (Student t-test; *P<0.05). (b) Nestin/hRAMP1 mice ate significantly less (Student t-test; 
*P<0.05), (c) ate fewer meals per day (Student t-test; *P<0.05) but (d) had increased meal size (Student 
t-test; *P<0.05), compared to controls. Data is represents as mean ± S.E.M. 
 
 
7.5.2 Genotype significantly influenced the feeding behavior of Nestin/hRAMP1 
mice maintained on chow. Moreover, the co-administration of amylin plus leptin 
significantly decreased food intake in the double transgenic mice. 
 
The genotype per se influenced the general feeding behavior of the double transgenic 
mice after all the individual treatments (Two-way ANOVA; P<0.05, Figures 
10,11,12). Acute amylin administration did not affect body weight, food intake, 
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number of meals consumed, or meal size, in Nestin/hRAMP1 mice or control; at any 
time point over the next 24 hours (here, shown at 4 and 24 hours; Figure 10). 
Unexpectedly, amylin treatment failed to reduce food intake.  
Leptin treatment and genotype significantly decreased food intake at 24h but not at 4h 
(Two-way ANOVA; P<0.05, Figure 11b) in double transgenic mice and a trend is 
present for the slightly diminished body weight (Figure 11a) and reduced number of 
meals (Figure 11c). Amylin and leptin co-administration significantly reduced food 
intake in Nestin/hRAMP1 mice at 24h (Bonferroni’s Post-hoc test; *P<0.05; Figure 
12b). The genotype also affected the decreased in body weight and in food intake at 
4h and 24h (Two-way ANOVA; *P<0.05, Figure 12a,b) in Nestin/hRAMP1 mice but 
no effect on number of meals (Figure 12c) nor on meals size (Figure 12d) was 
observed. 
 
 
!
! !
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!
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Figure 10: Meal pattern analysis after amylin treatment in mice maintained on chow. 
(
Body weight, food intake and meal pattern analysis of Nestin/hRAMP1 mice maintained on chow after 
acute amylin treatment (50 µg/kg). The genotype per se reduced (a) body weight, (b) food intake, (c) 
number of meals and (d) meal size (Two-way ANOVA; P<0.05) in Nestin/hRAMP1 mice, while no 
effect of treatment or interaction between genotype and treatment was observed. Data is represents as 
mean ± S.E.M. 
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Figure 11: Meal pattern analysis after leptin treatment in mice maintained on chow. 
 
Body weight, food intake and meal pattern analysis of Nestin/hRAMP1 mice maintained on chow after 
acute leptin treatment (5 mg/kg). (a) The body weight was lower in the double transgenic mice (Two-
way ANOVA; P<0.05). (b) Genotype and treatment decreased the food intake (Two-way ANOVA; 
P<0.05) and reduced (c) the number of meals at 24h (Two-way ANOVA; *P<0.05) in Nestin/hRAMP1 
mice, while no significant difference was observed (d) in the meal size. Data is represents as mean ± 
S.E.M. 
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Figure 12: Meal pattern analysis after amylin plus leptin treatment in mice maintained on chow. 
(
Body weight, food intake and meal pattern analysis of Nestin/hRAMP1 mice maintained on chow after 
acute amylin (50 µg/kg) and leptin treatment (5 mg/kg). (a) A significant effect of genotype was 
observed on body weight (Two-way ANOVA; P<0.01) in Nestin/hRAMP1 mice. (b) Genotype 
significantly affected food intake at 4h and 24h (Two-way ANOVA; P<0.05); at 24h, the 
administration of amylin plus leptin reduced the food intake (Two-way ANOVA; P<0.01) and food 
intake was significantly reduced by amylin and leptin in double transgenic mice (Bonferroni’s; 
*P<0.05). Neither amylin plus leptin treatment nor genotype affected the (c) number of meals or (d) 
meal size. Data is represents as mean ± S.E.M. 
!
 
7.5.3 Nestin/hRAMP1 mice maintained the lean phenotype after HFD challenge. 
Moreover, hRAMP1 seemed to slightly enhance leptin signaling. 
To investigate whether central hRAMP1 can protect against obesity, animals were 
challenged with HFD. Feeding behavior analysis showed that Nestin/hRAMP1 mice 
maintained a reduced body weight through the entire experiment (Student t-test; *P < 
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0.05; Figure 13a). No significant difference was observed in food intake, number of 
meals per day or meal size (Figure 13 b,c,d). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13:!Feeding behavior of Nestin/hRAMP1 mice maintained on HFD. 
!
Body weight, food intake and meal pattern analysis of Nestin/hRAMP1 mice maintained on HFD. (a) 
Body weight was significantly lower in double transgenic mice, compared to control (Student t-test; 
*P<0.05). No difference in (b) food intake, (c) number of meals per day nor (d) meal size was observed. 
Data is represents as mean ± S.E.M.!
 
 
Amylin treatment had no effect on the feeding behavior in the double transgenic mice 
or control while the genotype per se affected the decrease in body weight and in food 
intake at 4h and 24h (Two-way ANOVA; P<0.05; Figure 14a,b). No significant 
difference was observed in number of meals, nor meal size (Figure 14c,d). Genotype 
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per se reduced body weight after leptin administration (Two-way ANOVA; P<0.05, 
Figure 15a) in Nestin/hRAMP1 mice. Leptin treatment significantly reduced food 
intake at 24h, but not at 4h (Two-way ANOVA; P<0.05, Figure 15b) while no effect 
of the genotype was observed at neither time point. Neither the number of meals nor 
the meal size were affected by the treatment or the genotype at 4h and 24h (Figure 
15c,d). Finally, animals on HFD received an injection of amylin plus leptin. In 
Nestin/hRAMP1 mice the genotype significantly reduced the body weight (Two-way 
ANOVA; P<0.01, Figure 16a). The combined treatment of amylin plus leptin 
decreased food intake (Two-way ANOVA; P<0.01, Figure 16b) at 4 and 24h in 
double transgenic mice. Moreover, in control animals leptin significantly reduced 
food intake (Bonferroni’s post-hoc test; *P<0.01, Figure 16b) at 24h. In 
Nestin/hRAMP1 mice, amylin plus leptin treatment also reduced the number of meals 
at 4h and 24h (Two-way ANOVA; P<0.01, Figure 16c). Neither the genotype nor the 
treatment affected the meal size (Figure 16d). 
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Figure 14: Meal pattern analysis after amylin treatment in mice maintained on HFD. 
(
Body weight, food intake and meal pattern analysis of Nestin/hRAMP1 mice maintained on HFD, after 
acute amylin treatment (50 µg/kg). (a) Body weight and (b) food intake at 4h but not 24h, was 
decreased in double transgenic mice compared to control (Two-way ANOVA; P<0.05). No effect of 
genotype or treatment was observed in (c) the number of meals or (d) in the meal size. Data is 
represents as mean ± S.E.M. 
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Figure 15: Meal pattern analysis after leptin treatment in mice maintained on HFD. 
(
Body weight, food intake and meal pattern analysis of Nestin/hRAMP1 mice maintained on HFD, after 
acute leptin treatment (5 mg/kg). (a) Body weight was decreased by the genotype per se (Two-way 
ANOVA; P<0.05). (b) Leptin treatment significantly affected the reduction in food intake at 24h, but 
not at 4h (Two-way ANOVA; P<0.05) while no effect of the genotype was observed at either time 
point in Nestin/hRAMP1 mice. (c) Neither the number of meal nor (d) meal size were affected by 
treatment or genotype at 4h and 24h. Data is represents as mean ± S.E.M. 
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Figure 16: Meal pattern analysis after amylin plus leptin treatment in mice maintained on HFD. 
(
Body weight, food intake and meal pattern analysis of Nestin/hRAMP1 mice maintained on HFD, after 
amylin (50 µg/kg) and leptin (5mg/kg) treatment. (a) The genotype per se significantly reduced the 
body weight (Two-way ANOVA; P<0.01). (b) The combined treatment of amylin plus leptin decreased 
the food intake (Two-way ANOVA; P<0.01) at 4h and 24h. In control animals, leptin significantly 
reduced food intake (Bonferroni’s post-hoc test; *P<0.01) at 24h. (c) Amylin plus leptin treatment 
reduced the number of meal at 4h and 24h (Two-way ANOVA; P<0.01). (d) Neither the genotype nor 
the treatment affected the meal size. Data is represents as mean ± S.E.M.!
 
 
7.5.4 Nestin/hRAMP1 mice maintained on HFD seemed to have increased energy 
expenditure. 
To assess the potential effect of the neuronal expression of hRAMP1 on energy 
expenditure, mice were housed in metabolic cages. Double transgenic mice showed 
lower EE over 24h compared to control (Figure 17a). Furthermore, Nestin/hRAMP1 
mice seemed to maintain lower EE in both light and dark phases (Figure 17c). 
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However, when data was corrected for the body weight, our results demonstrated that 
the double transgenic mice actually displayed a significant increase in EE compared 
to control (Figure 17b), and this difference was maintained in both light and dark 
phases (Figure 17d). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Energy expenditure analysis of mice maintained on HFD. 
 
(a) Daily EE (cal/day/animal) of the Nestin/hRAMP1 mice was significantly lower compared to 
controls. (b) EE corrected for the body weight was significantly higher in double transgenic mice 
compared to control. (c) In Nestin/hRAMP1 mice EE was lower during both light and dark phases 
(12h/12h). (d) EE corrected for body weight was significantly higher in transgenic mice compared to 
controls. Data was analyzed using the Student’s t test;  * P < 0.05, ** P< 0.01. Data is represents as 
mean ± S.E.M. 
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7.6 Conclusions and future perspectives 
 
Our current work confirmed that Nestin/hRAMP1 mice have a marked lean phenotype 
(Zhang et al., 2011). Moreover, the meal pattern analysis showed that Nestin/hRAMP1 
mice have decreased food intake, reduced number of meals per day and increased 
meal size; thus supporting the role of RAMP1 in the regulation of energy metabolism. 
While ICV injection of amylin reduced food intake to weight gain ratio in previous 
studies (Fernandes-Santos et al., 2013; Zhang et al., 2011), unexpectedly, here, 
peripheral amylin administration failed to decrease feeding. Nestin/hRAMP1 mice 
express the hRAMP1 in addition to the constitutive mouse RAMP1, and this results in 
an overexpression of RAMP1 in the CNS. Recently, we demonstrated that acute 
amylin treatment down-regulated RAMP1 mRNA in single AP-neurons, suggesting 
that amylin self-modulates the accessory subunits of its own receptor in this brain area 
(Liberini et al., 2016). Whether a similar mechanism happens in other brain nuclei is 
not known yet. We speculate that one possibility for the lack of amylin effect might 
be that the overexpression of RAMP1 may lead to a diminished response in the AP-
neurons. Thus resulting in a blunted amylin effect to reduce food intake. Further 
studies are still required to investigate the long-term behavior of the RAMPs in 
response to amylin. 
 
However, the genotype per se significantly affected the general feeding behavior of 
Nestin/hRAMP1 mice. Similarly, leptin treatment displayed a trend in the reduction of 
food intake, body weight and number of meals consumed in Nestin/hRAMP1 mice, 
although it did not reach statistical significance. The co-administration of amylin plus 
leptin reduced food intake in double transgenic mice, suggesting a potentiation of the 
synergistic effect previously described in non-transgenic rodents (Roth et al., 2008; 
Trevaskis et al., 2010b; Turek et al., 2010). It remains to be addressed which brain 
areas are involved in the maintenance of the lean phenotype and where the amylin-
leptin interaction takes place. A potential candidate appears to be the AP. Indeed, 
recent work from our group demonstrated that 30% of single amylin-activated AP-
neurons co-expressed the LepRb mRNA, in addition to the mRNA of all the 
necessary components to form a functional AMY (Liberini et al., 2016). This suggests 
the existence of a first-order neuronal population in the AP that is responsive to both 
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amylin and leptin. Further, LepRb expression was up-regulated after acute amylin 
treatment in single AP-neurons (Liberini et al., 2016), indicating that amylin might 
enhances leptin sensitivity in this brain area. However, the VMH and the VTA could 
also play a role in amylin-leptin interaction (Le Foll et al., 2015; Li et al., 2015; 
Mietlicki-Baase et al., 2015a). Fos immunohistochemistry studies or studies using 
other activation markers to identify the central pathways activated by amylin and/or 
leptin are still missing.  
A limitation of this mouse model is that the expression of the hRAMP1 is not 
restricted to any specific brain nuclei but it is expressed throughout the entire CNS. 
Therefore, neurons that ectopically carry RAMP1 in different brain areas, might also 
contribute to the enhanced metabolic effect. A viral-mediated approach would be the 
strategy to selectively study the effect of RAMP1 in specific brain areas. 
 
Finally, we also demonstrated that the characteristic lean phenotype of the 
Nestin/hRAMP1 is maintained when animals are challenged on HFD and this is 
possibly the result of an increase in EE. However, our data are only preliminary and 
describe the situation in the short-term period. Long-term studies would be 
instrumental to further characterize the role of RAMP1 to possibly protect from 
obesity. Moreover, bodies CT-scan analysis is required to evaluate the distribution of 
the lean and the fat mass and to correct the metabolic rate for lean mass. Furthermore, 
excluding a role of locomotor activity and core temperature would be essential to 
fully characterize the maintenance of the lean phenotype.  
 
All together, these data suggest that, despite the diet, Nestin/hRAMP1 mice are leaner 
compared to their control and that the reduced body weight is the result of an 
increased EE rather than a decrease in food intake. Hence, the Nestin/hRAMP1 mice 
seem to be an effective model to investigate RAMP1-mediated effect on energy 
homeostasis.  
 
 
7.6.1 Outlooks 
 
As mentioned in the experimental design section, brains and carcasses of the 
Nestin/hRAMP1 mice have been store for future investigation.  
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In this section I will describe the expected outcomes.! 
 
 
Outlook 1 
c-Fos is a well known marker of neuronal activation. Amylin induced-Fos response 
has been documented in several brain areas, including the AP (Braegger et al., 2014; 
Potes et al., 2010b). Experiment 2 was aimed to determine amylin-induced patterns of 
c-Fos activation in the brains of double transgenic mice expressing hRAMP1 and in 
non-transgenic controls, maintained on HFD. Since the AP is a principle site of 
amylin action, and together with the hypothalamus seems also to be an area where 
amylin and leptin interaction might occur (Le Foll et al., 2015; Li et al., 2015; 
Mietlicki-Baase et al., 2015a), Fos-IHC will be investigate in these brain nuclei. We 
hypothesized that amylin administration would result in an increased neuronal 
activation in the AP and in some hypothalamic areas (e.g; VMH and LH) in 
Nestin/hRAMP1 mice. Further, to confirm that the Fos-activated neurons potentially 
bear an AMY, we aim to perform a double staining of the tissue sections for 
Fos/CTR. CTR is the core subunit of the AMY and would be indicative of the 
presence of AMYs. Unfortunately, good RAMP antibodies are not commercially 
available. We expect to find a broad overlap of Fos and CTR staining, demonstrating 
that AMYs are present and mediate the amylin effect in these brain areas.  
 
Outlook 2 
Obesity is typically associated with leptin-resistance (Shimizu et al., 2007) and the 
failure in this signaling system broadly contributes to weight gain. Following close 
examination of basal ingestive behavior in Nestin/hRAMP1 mice maintained on HFD, 
leptin response would be investigated by measuring pSTAT3, a known marker for 
leptin-induced activation. We speculate that Nestin/hRAMP1 mice would show an 
increased leptin-sensitivity. Moreover, if activation of AMYs is somehow permissive 
for leptin’s effect, we expect that hRAMP1 expression would enhance pSTAT3 
signaling in both hypothalamic and hindbrain nuclei.  
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Outlook 3 
The maintenance of the homeostasis is fundamental in the control of energy balance. 
Several lines of evidence demonstrate that acute and chronic amylin administration 
increases EE in rodents maintained on chow (Mack et al., 2007; Roth et al., 2006). 
Moreover, preliminary results from Experiment 3 demonstrated that Nestin/hRAMP1 
mice have an increased EE on HFD. The carcasses will be CT-scanned to evaluate the 
body composition of fat and lean mass. We expected to find a reduction in the fat 
mass but not in the lean mass of the double transgenic mice. Finally, the same cohort 
of animals was acutely treated with amylin. Our hypothesis is that amylin would 
increase EE in the transgenic mice. 
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8. Discussion 
 
Since the individual studies have been discussed in detail in the respective sections, I 
will now only briefly summarize the general results and focus on potential links 
between the studies and try to draw general conclusions from the entire set of 
experiments.    
Obesity represents a high risk for the health status, and in 2014 it affected up to 40% 
of the population (WHO, 2014). Excessive fat mass is associated with an increased 
risk of cardiovascular, metabolic and gastrointestinal comorbidities (Haslam and 
James, 2005). Moreover, severe adiposity is also known to affect the brain by 
increasing the risk to develop neurodegenerative disorders (Arvanitakis et al., 2004; 
de la Monte and Tong, 2014). Despite the influence of social and other factors, a 
complex physiological system is in charge of the maintenance of the energy balance. 
Hormones involved in the control of feeding behavior, such as insulin, amylin, 
cholecystokinin, leptin, ghrelin and glucagon-like peptide-1 (to mention the most 
important ones) inform the brains about the overall energy status of the body and all 
interact to maintain the equilibrium. A deep understanding of the physiological 
processes regulating energy balance is essential not only to fight obesity, but also to 
shed light on how obesity affects the brain. 
The satiating hormone amylin exerts its actions mainly by binding to the AMY in the 
AP (Potes and Lutz, 2010; Riediger et al., 2001). Amylin decreases food intake and 
body weight by reducing the number of meals without any compensatory effect on the 
meal size (Lutz et al., 1995). Like insulin and leptin, amylin also shares the 
characteristics of an adiposity signal. In fact, chronic amylin treatment clearly reduced 
body weight gain, specifically by decreasing fat mass, in both rodents and humans 
(Arnelo et al., 1996; Mack et al., 2007; Roth et al., 2006). Moreover, central amylin 
administration increased energy expenditure via a mechanism that might involve the 
activation of the sympathetic nervous system, which results in an increased 
thermogenic activity of the BAT (Fernandes-Santos et al., 2013; Zhang et al., 2011). 
Despite its main role in feeding behavior, amylin has recently been shown to act as a 
neurotrophic factor: it induces the formation of neuronal projection from the AP to the 
NTS in neonatal mice (Lutz, 2010b), it recovers impaired AP and hippocampal 
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neurogenesis in female rats after ovariectomy (Trevaskis et al., 2010c) and the amylin 
analogue pramlintide restores cognitive function in a mouse model of AD (Adler et 
al., 2014). Hence, amylin is involved in the regulation of feeding behavior and also 
participates in neurogenic processes. 
 
8.1. Effect of acute amylin administration on the AP 
The two main studies described here provided new insight on the metabolic and 
neurogenic effects of amylin in the rodent AP. To exert its effects, amylin needs to 
bind to the AMYs, which are predominantly present in the AP (Potes and Lutz, 2010; 
Riediger et al., 2001). A functional AMY is a heterodimer of the core subunit CTRa 
with a member of the regulatory proteins RAMPs. Previous studies demonstrate that 
CTRa and the RAMPs are both present in the rodent AP (Christopoulos et al., 1999; 
Tilakaratne et al., 2000; Watkins et al., 2014), however evidence of co-expression of 
these subunits in the same cell in native tissue was still missing. Therefore, we 
hypothesized that CTRa and the RAMPs are co-expressed in single amylin-activated 
AP-neurons. Our findings revealed that in the AP, CTRa mRNA is constitutively co-
expressed with one or more RAMPs mRNAs (Figure 18, point 1). Furthermore, acute 
amylin injection seems to modulate its own receptors: while CTRa expression 
remains un-affected, RAMP1 and RAMP3 are down-regulated by amylin. On the 
contrary, RAMP2 expression is up-regulated (Figure 18, point 2). These results 
support the concept that CTRa is the structural subunit of the AMY, while the 
RAMPs are the dynamic regulatory subunits. Moreover, amylin seems to trigger a 
negative feedback regulatory mechanism on its own receptors, as it was shown for 
other hormones, such as glucocorticoids (Rosewicz et al., 1988). Our data also depict 
a scenario in which more than one RAMP is normally co-expressed with CTRa in 
amylin-activated AP-neurons. While RAMP3 and RAMP1 transcripts were found 
independently or in combination with CTRa, RAMP2 co-expression with CTRa 
seemed to be linked to the presence of either RAMP1 and/or RAMP3. This supports 
the knowledge that AMY1 and AMY3 are the major AMYs, while AMY2 probably 
function as ADM receptor in the AP (Stachniak and Krukoff, 2003). It remains to be 
addressed whether different physiological roles of amylin are mediated by different 
combination of the AMY subunits. One possibility is that each RAMP might 
contribute to a specific physiological effect of amylin. Nestin/hRAMP1 mice, which 
express the human RAMP1, are characterized by a decreased body weight throughout 
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lifespan, thus displaying a marked lean phenotype (Zhang et al., 2011). The reduction 
in body weight seemed to be achieved by an increase in the EE rather than by a 
reduction of eating (Zhang et al., 2011). Indeed, our unpublished data (see ¶7.1) 
further support this hypothesis: Nestin/hRAMP1 mice maintained the lean phenotype 
when challenged with HFD, and this resulted from an increased in EE rather than 
from a decreased feeding. All together these findings suggest that RAMP1 might be 
preferentially involved in the control of EE rather than in the control of food intake. 
After acute amylin administration, RAMP2 mRNA expression was elevated in single 
AP-neurons. An explanation could be that RAMP2 upregulation is necessary to allow 
the dimerization of RAMP2 with the CLR to generate an ADM receptor over an 
AMY2. In vitro studies demonstrated that ADM directly elicits excitatory effects on 
rodent AP-neurons (Allen and Ferguson, 1996). Moreover, the central action of the 
ADM is to delay gastric empting (Martinez et al., 1997). Amylin contributes to slow 
the gastric empting (Young et al., 1995), but the exact mechanism is still unknown. 
Therefore, we speculate that amylin might indirectly exert its effect to delay gastric 
empting by increasing the sensitivity of the AP-neurons to ADM.  
RAMP3 was the predominant transcript co-expressed with CTRa, either alone or in 
combination with RAMP1 and/or RAMP2 in individual amylin-activated AP-neurons. 
Further, in vitro studies demonstrated that AMY3 is the most potent AMY (Bailey et 
al., 2012). Speculating that RAMP1 might be involved in the regulation of EE and 
RAMP2 in the slowing of the gastric empting, RAMP3 might mediate amylin’s action 
to decrease food intake. RAMP1 and/or RAMP3 knockdown mice are now available 
in our laboratory (RAMP2 knockdown model is not viable). These transgenic models 
would be instrumental tools to investigate the role of different RAMPs in different 
physiological effect of amylin.  
 
Interestingly, 30% of the neuronal population that co-expressed all the necessary 
components to form a functional AMY, also co-expressed the LepRb mRNA (Figure 
18, point 3). Moreover, acute amylin stimulation resulted in an increase of LepRb 
transcript. These findings describe a neuronal population in the AP that is responsive 
to both amylin and leptin, suggesting that the AP might be one of the brain sites that 
may mediate amylin and leptin interaction. Future studies addressing the effect of 
acute leptin and amylin plus leptin treatments would be instrumental to assess a 
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potential role of leptin to directly activate individual AP-LepRb and whether the co-
administration of amylin and leptin could synergistically increase the LepRb mRNA 
level. 
AMY subunits might not be the only factors differentially regulated by acute amylin 
treatment. Therefore, to provide a full picture of the acute amylin effect, we analyzed 
the full AP transcriptome. Interestingly, our analysis revealed that amylin essentially 
affected genes involved in the regulation of neurogenesis-like processes. Indeed, 
pathway analysis showed that Ephrin and GABAA signaling, which regulate multiple 
stage of neurogenesis, are the two major processes regulated by amylin.  
Worthy of note, reward circuits (Dopamine-2 and Mu-opiod receptor pathways) are 
also affected by acute amylin treatment. It has been shown that VTA-neurons that 
carry AMYs, control energy balance by negative modulation of dopamine signaling in 
the nucleus accumbens (NAc) (Mietlicki-Baase et al., 2015b). Further, AMYs located 
in the shell of the NAc directly antagonized the hunger-induced behavior of mu-
opioid receptors (Baisley and Baldo, 2014). Work from our group (Potes et al., 2012) 
demonstrated that 20% of AP-neurons characterized as pERK-positive after amylin 
administration are noradrenergic (DBH-neurons). These findings suggest that amylin 
might possibly act on AP-neurons to indirectly activate the reward circuit. Future 
studies are still required to deepen the role of AP-AMYs signaling in reward 
behavior. Moreover, results from the GO enrichment analysis demonstrated that genes 
affecting synaptic transmission, nervous system development and generation of 
neurons are also regulated by acute amylin treatment. The transcription factor 
NeuroD1, which is required in the final step of neuronal differentiation during post-
natal neurogenesis, appears to be involved in all the aforementioned processes. 
Precisely, NeuroD1, is consistently up-regulated by acute amylin injection, while the 
administration of AC187 completely reverses this effect; supporting a direct effect of 
amylin on gene transcription (Figure 18, point 4). Hence, these findings highlight the 
potential role of amylin in the regulation of neurogenesis-like processes. 
 
8.2 Chronic effects of amylin on the AP 
Until recently, adult neurogenesis was described only in two brain areas, the SGZ 
(Eriksson et al., 1998; Kempermann and Gage, 2000) and SVZ (Doetsch et al., 1999). 
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However, it is now accepted that adult neurogenesis also happens in the CVOs 
(Bennett et al., 2009; Hourai and Miyata, 2013; Lin et al., 2015). The AP, as a CVO, 
is thus considered a newly discovered neurogenic niche in the adult mammalian brain. 
Because acute amylin injections affected several gene pathways and processes leading 
to the generation of new neurons, we hypothesized that chronic amylin administration 
would increase the constitutive neurogenesis in the rodent AP. In fact, our results 
demonstrated that sustained amylin infusion, not only decreased food intake, but 
significantly increased the number of newly proliferating cells in the adult AP (Figure 
18, point 5) and drove the cell differentiation into a neuronal rather than glia lineage 
(Figure 18, point 6). These findings are consistent with previous evidence showing 
that amylin has the potential to protect from neuronal damages and to rescue impaired 
neurogenic functions (Adler et al., 2014; Trevaskis et al., 2010c). 
However, the physiological relevance of the neurogenic effect of amylin in the AP is 
not known yet. The lack of a fully functional BBB makes the AP a “window of the 
brain”, thus exposing it to all the potentially dangerous substances circulating in the 
blood, which may in turn damage the AP-neurons. Also, chronic amylin infusion 
might generate the necessity to activate more amylin-responsive neurons to avoid the 
instauration of amylin sensitivity. Therefore, the AP-ability of self-renewing could be 
a protective mechanism to maintain a functional signal regarding the energetic status 
of the body. 
Still, many open questions remain to be answered. There is the need to understand 
which role these newly-formed neurons are engaged in and how they are integrated 
into the pre-existing neuronal circuits. Moreover, it would be fundamental to 
understand which mechanisms are involved in the amylin-mediated adult 
neurogenesis. Previous studies demonstrate that amylin signaling involves the 
activation of ERK1/2 cascade and that pERK AP-neurons partially overlap with CTR 
AP-neurons (Potes et al., 2010b). Moreover the number of ERK phosphorylated 
neurons is higher 10-15 minutes after amylin stimulus, exactly when the satiating 
effect is at its maximum and thus proving a direct role of amylin on AP-neurons (Lutz 
et al., 1995; Potes et al., 2012). Furthermore, in ERK knockdown mice neurogenesis 
was shown to be abnormal, suggesting that a functional ERK1/2 signaling is required 
for the generation of new neurons (Satoh et al., 2011). All together, these results 
imply that amylin might induce neurogenesis by activating ERK1/2 cascade in the 
AP. Further studies are still required to investigate this possibility. Blocking ERK 
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signaling in the AP or administer acute and chronic amylin in ERK knockout mice 
would contribute to a better understanding of the amylin’s mechanism in adult 
neurogenesis. Moreover, to investigate the potential of amylin to induce neurogenesis 
in other brain areas where constitutive neurogenesis already occurs (e.g; SGZ and 
SVZ) would be of great interest to evaluate the neurogenic capacity of amylin.  
 
In conclusion, the work presented in this thesis confirms the fundamental role of 
amylin in the control of feeding behavior and energy balance and presents a novel 
role of amylin in the process of adult neurogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Effects of acute and chronic amylin administration on the rat AP. 
 
Acute and chronic amylin administration decreased food intake and body weight in rodents. (1) All the 
necessary components to generate a functional AMY are co-expressed in single amylin-activated AP-
neurons. (2) Acute amylin acts via a negative feedback regulatory mechanism to down-regulate 
RAMP1 and RAMP3, while RAMP2 and (3) LepRb were upregulated. Acute Amylin also regulated 
genes involved in neurogenic processes. (4) The transcriptional factor NeuroD1 was consistently up-
regulated. Chronic amylin infusion (5) increased the number of newly proliferating BrdU-labeled cells 
in the AP, and  (6) promoted the cell maturation into neurons rather than glia.
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9. Abbreviations 
 
AD   Alzheimer’s disease 
ADM   adrenomedullin  
AMY   amylin receptor 
Arc   nucleus arcuatus 
AP                    area postrema 
BAT    brown adipose tissue 
BBB   blood brain barrier 
bHLH    beta helix-loop-helix 
CLR   calcitonin-like receptor 
CNS   central nervous system 
CVO                 circumventricular organ  
CTRa                  calcitonin-receptor isoform a 
DG   dentate gyrus 
DMH                 dorso-medial hypothalamus  
EE                      energy expenditure  
EphRs   ehprin receptors 
ERK1/2  extracellular signal-regulated kinase 1 and 2 
GO   gene ontology 
HFD   high fat diet 
JAK2/STAT3   janus kinase 2/signal transducer and activator of transcription 3 LBP!! ! ! lateral parabrachial nucleus 
LepRb   leptin receptor isoform b 
LH   lateral hypothalamus 
LHA   lateral hypothalamic area 
ME   median eminence 
NAc   nucleus accumbens 
NeuroD  neuronal differentiation-1 
NeuroD1  neuronal differentiation-1 
NGS   next-generation sequencing  
NSC   neural stem cell 
NTS   nucleus tractus solitarious 
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OVLT   organum vasculosum of the lamina terminalis 
PB   parabrachial nucleus 
RAMP1  receptor-activity modifying protein-1 
RAMP2  receptor-activity modifying protein-2 
RAMP3  receptor-activity modifying protein-3 
sCT   salmon-calcitonin 
SGZ   subgranular zone 
SFO   subfornical organ 
SVZ   subventricular zone 
T2D   type 2 diabetes 
VMH   ventro medial hypothalamus 
VTA   ventral tegmental area 
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